V√§stra G√∂talandsregionen\r\nSahlgrenska Universitetssjukhuset, HTA-centrum\r\nHealth Technology Assessment\r\nHTA-rapport 2014:66\r\n\r\nLeft Ventricular Assist Device as Permanent Support in\r\nPatients with End-Stage Heart Failure\r\nKarason K, Dellgren G, Isaksson E, Lid√©n H, Liljegren A,\r\nRedfors B, Sj√∂gren P, Svanberg T, Samuelsson O \r\n HTA-report: LVAD in heart failure 2(22)\r\nLeft Ventricular Assist Device as Permanent Support in\r\nPatients with End-Stage Heart Failure\r\n[LVAD som permanent behandling vid terminal hj√§rtsvikt]\r\nRunning title: LVAD in heart failure\r\nKarason K1*, Dellgren G2\r\n, Isaksson E1\r\n, Lid√©n H2\r\n, Liljegren A3\r\n, Redfors B4\r\n, Sj√∂gren P5\r\n, Svanberg T3\r\n,\r\nSamuelsson O5\r\n¬π Department of Cardiology\r\n2 Department of Cardiothoracic Surgery\r\n3 Medical Library\r\n4 Department of Cardiothorasic Anaesthesia and Intensive Care\r\n5 HTA-centre of Region V√§stra G√∂taland\r\nall at Sahlgrenska University Hospital, G√∂teborg, Sweden\r\n*Corresponding author\r\nPublished February 2014\r\n2014:66\r\nSuggested citation: Karason K, Dellgren G, Redfors B, Isaksson E, Lid√©n H, Liljegren A, Sj√∂gren P, Svanberg T,\r\nSamuelsson O. Left Ventricular Assist Device as permanent support in patients with terminal heart failure\r\n[LVAD som permanent behandling vid terminal hj√§rtsvikt]. G√∂teborg: V√§stra G√∂talandsregionen, Sahlgrenska\r\nUniversitetssjukhuset, HTA-centrum; 2014. Regional activity-based HTA 2014:66 \r\n HTA-report: LVAD in heart failure 3(22)\r\nTable of content\r\nParticipants................................................................................................................................... 4\r\nSummary of the Health Technology Assessment ........................................................................ 5\r\nSwedish Summary of the Health Technology Assessment.......................................................... 7\r\nAbbreviations............................................................................................................................... 9\r\nThe Patient Category and the Present Treatment....................................................................... 10\r\nThe New Health Technology ‚Äì Left Ventricular Assisted Device............................................. 13\r\nThe Central Question at Issue .................................................................................................... 15\r\nReview of the Quality of Evidence ............................................................................................ 16\r\nEthical Aspects........................................................................................................................... 20\r\nOrganisation ............................................................................................................................... 20\r\nEconomy Aspects ....................................................................................................................... 21\r\nUnanswered Questions............................................................................................................... 22\r\nAppendix 1 Search strategy, study selection and references\r\nAppendix 2 Included studies ‚Äì design and patient characteristics\r\nAppendix 3 Excluded articles\r\nAppendix 4 Outcome tables PICO 1\r\nAppendix 5 Outcome tables PICO2\r\nAppendix 6 Complications\r\nAppendix 7 Summary of findings (SoF)-table\r\nAppendix 8 Ethical analyses \r\n HTA-report: LVAD in heart failure 4(22)\r\nParticipants\r\nParticipants in the HTA group\r\nG√∂ran Dellgren, MD, Associate professor, Consultant Cardiothoracic Surgery, Director Heart and\r\nLung Transplantation\r\nKristjan Karason, MD, Phd, Consultant Cardiology, Director Transplant Cardiology\r\nBengt Redfors, MD, PhD, Consultant Cardiothoracic Anesthesia and Intensive Care\r\nHans Lid√©n, MD,PhD, Consultant, Cardiothoracic Surgery\r\nEwa Isaksson, Nurse coordinator, Heart Failure Outpatient Clinic\r\nAll at the Sahlgrenska University Hospital, G√∂teborg, Sweden\r\nFrom the HTA centre\r\nOla Samuelsson, MD, Associate professor, Petteri Sj√∂gren, DDS, PhD, and Therese Svanberg,\r\nlibrarian. All at HTA centrum, Sahlgrenska University Hospital, G√∂teborg, Sweden\r\nAnn Liljegren, librarian, Medical Library, Sahlgrenska University Hospital, G√∂teborg, Sweden\r\nWho posed the question?\r\nOlof Ekre, Chairman, Department of Cardiothoracic Surgery, Anesthesia, Intensive Care and\r\nVascular Surgery, Sahlgrenska University Hospital, G√∂teborg, Sweden, and G√∂ran Matejka,\r\nChairman, Department of Cardiology, Sahlgrenska University Hospital, G√∂teborg, Sweden\r\nExternal reviewers\r\nAnders Larsson, MD, Department of Neurology, S√∂dra √Ñlvsborg Hospital, Sweden\r\nKarl Swedberg, Professor emeritus in Cardiology, Sahlgrenska Academy, G√∂teborg, Sweden\r\nAre there any conflicts of interest for the proposer or any of the participants in the HTA\r\ngroup?\r\nNo\r\nThe HTA was accomplished during the period of 2013-02-21 ‚Äì 2013-12-11.\r\nThe last literature search was updated in February 2013\r\nThe Regional Health Technology Assessment Centre (HTA-centrum) of Region V√§stra G√∂taland, Sweden (VGR) has\r\nthe task to make statements on HTA reports carried out in VGR. The statement should summarise the question at\r\nissue, results and quality of evidence regarding efficacy and risks, and economical and ethical aspects of the\r\nparticular health technology that has been assessed in the report.\r\nChristina Bergh, Professor, MD\r\nHead of HTA-centrum of Region V√§stra G√∂taland, Sweden\r\nHTA quality assurance group, Region V√§stra G√∂taland, Sweden\r\nChristina Bergh\r\nMD, Professor\r\nAnders Larsson\r\nMD, PhD\r\nMaria Skogby\r\nRN, PhD\r\nThomas Franz√©n\r\nHead of hospital library\r\nChristian Rylander\r\nMD, PhD\r\nAnnika Strandell\r\nMD, Associate professor\r\nMagnus Hakeberg\r\nOD, Professor\r\nOla Samuelsson\r\nMD, Associate professor\r\nTherese Svanberg\r\nHTA-librarian\r\nLennart Jiveg√•rd\r\nMD, Senior university lecturer\r\nHenrik Sj√∂vall\r\nMD, Professor\r\nKjell-Arne Ung\r\nMD, Associate professor\r\nPeter Johansson\r\nMD, PhD\r\nPetteri Sj√∂gren\r\nDDS, PhD\r\n HTA-report: LVAD in heart failure 5(22)\r\nSummary of the Health Technology Assessment\r\nMethod and patient group\r\nSubjects with severe heart failure are most commonly treated with pharmacological therapy. In\r\nselected cases an implantable automatic defibrillator and/or resynchronisation therapy may be of\r\nadditional benefit. However, in some patients with end-stage heart failure these therapies are\r\ninsufficient. Mechanical circulatory support (MCS) can be an alternative in these subjects. The\r\ngoal of MCS is to support the circulation until transplantation (bridge to transplantation), or until\r\nthe heart recovers (bridge to recovery), or as a permanent treatment option. The third alternative,\r\nwhich is called destination therapy (DT), is a possible option for selected patients who are not\r\neligible for heart transplantation due to advanced age or comorbidities.\r\nQuestion at issue:\r\nDoes mechanical circulatory support with left ventricular assist devices (LVAD) reduce\r\nmorbidity, improve quality of life, and prolong survival in patients with end-stage heart failure\r\nnot eligible for heart transplantation in comparison to optimal medical treatment?\r\nPatients, Intervention, Comparison, Outcome (PICO1 and PICO2)\r\nP = Patients with end-stage left ventricular heart failure despite optimal medical treatment\r\nI1 = Left ventricular assist device with pulsatile flow (PF-LVAD)\r\nC1= Optimal medical treatment (OMT)\r\nI2 = Left ventricular assist device with continuous flow (CF-LVAD)\r\nC2= Left ventricular assist device with pulsatile flow (PF-LVAD)\r\nO = Survival, quality of life (QoL), functional capacity (NYHA classification, 6 minute walk test,\r\nexercise test) and biomarkers of heart failure. Complications such as infections,\r\nhaemorrhages, thromboembolic events, neuropsychological functions\r\nStudied risks and benefits for patients of the new health technology\r\nThe systematic literature search identified one randomised controlled trial (RCT) and one nonrandomised\r\ncontrolled study that have evaluated the effects of PF-LVAD in comparison to OMT,\r\nand one RCT and two non-randomised controlled studies that have evaluated the effects of PFLVAD\r\nin comparison to CF-LVAD in patients with terminal heart failure.\r\nPulsatile flow LVAD in comparison to optimal medical management (PICO1)\r\nConclusions: Pulsatile LVAD as destination therapy probably increases survival (GRADE\r\nÔÉÖÔÉÖÔÉÖÔ??), and may improve the functional capacity (GRADE ÔÉÖÔÉÖÔ??Ô??) in patients with terminal\r\nleft ventricular heart failure in comparison with OMT. It is uncertain whether the treatment has\r\nany effect on quality of life (GRADE ÔÉÖÔ??Ô??Ô??)\r\nContinuous flow LVAD in comparison to pulsatile flow LVAD (PICO2)\r\nConclusions: Continuous flow LVAD as destination therapy probably increases survival in\r\npatients with terminal left ventricular heart failure in comparison with PF-LVAD (GRADE\r\nÔÉÖÔÉÖÔÉÖÔ??). While both PF and CF flow devices have been shown to improve quality of life and\r\nfunctional outcome compared to baseline, there is only low quality evidence that CF may improve\r\nquality of life more than PF (GRADE ÔÉÖÔÉÖÔ??Ô??), and it is uncertain whether the effect on\r\nfunctional capacity differs between CF and PF. (GRADE ÔÉÖÔ??Ô??Ô??). \r\n HTA-report: LVAD in heart failure 6(22)\r\nComplications\r\nLong-term MCS is hampered by several complications such as device malfunction, infections (20\r\n‚Äì 60 \%), bleeding (15 ‚Äì 30 \%), thromboembolic events (5 ‚Äì 25 \%) and right ventricular failure\r\n(10 ‚Äì 40 \%). The rate of adverse events has steadily declined over time with improved techniques.\r\nEthical aspects\r\nIntroduction of a DT program raises several ethical issues. The self-esteem and self-image of the\r\nindividual patient probably vary between subjects, but may be affected in both positive and\r\nnegative ways. The patient will still be dependent on assistance from family members and/or\r\nhealth care providers, and the physical integrity is affected. Without additional economic\r\nresources there is a substantial risk that DT will reallocate current resources from the needs of\r\nother patient categories.\r\nEconomical aspects\r\nThe present cost for the currently most used continuous flow device, the HeartMate II, is 750 000\r\nSEK (about 82 000 ‚Ç¨) with an additional 125 000 SEK (ÔÇª14 000 ‚Ç¨) for necessary accessories. At\r\nSahlgrenska University hospital eight patients had a HeartMate II implanted as MCS for 12\r\nmonths or longer during 2010-2012. The average cost per patient for the first year was about 1.5\r\nmillion SEK (about 160 000 ‚Ç¨).\r\nConcluding remark:\r\nTreatment with LVAD as DT increases survival in patients with terminal heart failure. It is costly\r\nand hampered by several serious complications. During the last decade costs have come down\r\nand the rate of complications have started to decline.\r\n HTA-report: LVAD in heart failure 7(22)\r\nSwedish Summary of the Health Technology Assessment\r\nMekaniskt v√§nsterkammarst√∂d som permanent behandling vid terminal hj√§rtsvikt\r\nMetod och m√•lgrupp:\r\nAvancerad hj√§rtsvikt behandlas huvudsakligen farmakologiskt. I utvalda fall kan en automatisk\r\ndefibrillator eller s√• kallad resynkroneringsterapi s√§ttas in i hj√§rtat. Hos en del patienter med\r\nuttalad hj√§rtsvikt √§r dessa behandlingar emellertid inte tillr√§ckligt effektiva. Ett alternativ √§r d√•\r\nmekaniskt cirkulationsst√∂d (MCS). M√•let med MCS √§r att ge cirkulatoriskt st√∂d i v√§ntan p√•\r\nhj√§rttransplantation (‚Äúbridge to transplantation‚Ä?), eller tills hj√§rtfunktionen √•terh√§mtar sig (‚Ä?bridge\r\nto recovery‚Ä?), eller som permanent st√∂djande behandling. Det sistn√§mnda ben√§mns ‚Äúdestination\r\ntherapy‚Ä? (DT), och √§r en m√∂jlig behandling hos utvalda patienter som p√• grund av √•lder eller\r\nannan sv√•r samtidig sjuklighet inte √§r kandidater f√∂r hj√§rt transplantation. Denna HTA-utredning\r\nomfattar denna sistn√§mnda patientgrupp.\r\nFr√•gest√§llning:\r\nMinskar v√§nsterkammarst√∂d med mekanisk cirkulatorisk terapi, ‚Äúleft ventricular assist devices\r\n(LVAD)‚Ä? d√∂dlighet och sjuklighet hos patienter med terminal hj√§rtsvikt, och f√∂rb√§ttras deras\r\nlivskvalitet j√§mf√∂rt med optimal medicinsk behandling?\r\nPICO\r\nP = Patienter med sv√•r kronisk v√§nsterkammarsvikt, trots optimal medicinsk behandling\r\nI1 = Mekaniskt v√§nsterkammarst√∂d f√∂r permanent bruk med pump som ger pulsativt fl√∂de\r\n(PF-LVAD)\r\nC1 = Optimal medicinsk handl√§ggning\r\nI2 = Mekaniskt v√§nsterkammarst√∂d f√∂r permanent bruk med pump som ger kontinuerligt\r\nfl√∂de (CF-LVAD)\r\nC2 =Mekaniskt v√§nsterkammarst√∂d f√∂r permanent bruk med pump som ger pulsativt fl√∂de\r\n(PF-LVAD)\r\nO = √ñverlevnad, livskvalitet, funktionsf√∂rm√•ga (NYHA, 6 MWT, arbetsprov) och andra\r\nmark√∂rer f√∂r hj√§rtsvikt, samt infektioner, bl√∂dningar, tromboembolism och\r\nneuropsykologiska funktioner\r\nKunskapsl√§ge och evidensgradering:\r\nDen systematiska litteraturs√∂kningen identifierade en randomiserad kontrollerad studie (RCT)\r\noch en icke-randomiserad kontrollerad studie som analyserat effekten av PF-LVAD j√§mf√∂rt med\r\noptimal medicinsk behandling, och en RCT och tv√• icke-randomiserade kontrollerade studier som\r\nanalyserat effekten av PF-LVAD j√§mf√∂rt med CF-LVAD hos patienter med terminal hj√§rtsvikt.\r\nLVAD med pulsativt fl√∂de j√§mf√∂rt med optimal medicinsk behandling (PICO1)\r\nSlutsatser: I j√§mf√∂relse med optimal medicinsk behandling f√∂rl√§nger LVAD med pulsativt fl√∂de,\r\nsom ‚Ä?destination therapy‚Ä?, √∂verlevnaden hos patienter med terminal hj√§rtsvikt (GRADE ÔÉÖÔÉÖÔÉÖÔ??).\r\nBehandlingen kan f√∂rb√§ttra patienternas funktionsf√∂rm√•ga (GRADE ÔÉÖÔÉÖÔ??Ô??), men det √§r os√§kert\r\nom den har n√•gon effekt p√• livskvalitet (GRADE ÔÉÖÔ??Ô??Ô??).\r\n HTA-report: LVAD in heart failure 8(22)\r\nLVAD med kontinuerligt fl√∂de j√§mf√∂rt med LVAD med pulsativt fl√∂de (PICO2)\r\nSlutsatser: I j√§mf√∂relse med LVAD med pulsativt fl√∂de f√∂rl√§nger LVAD med kontinuerligt fl√∂de\r\n√∂verlevnaden hos patienter med terminal hj√§rtsvikt (GRADE ÔÉÖÔÉÖÔÉÖÔ??). S√•v√§l livskvalitet som\r\nfunktionsf√∂rm√•ga f√∂rb√§ttras troligen av b√•da behandlingarna men det vetenskapliga underlaget\r\nsom st√∂d f√∂r att CF-LVAD och PF-LVAD skiljer sig √•t i effekt √§r begr√§nsat (GRADE ÔÉÖÔÉÖÔ??Ô??).\r\nDet √§r √§ven os√§kert om de har olika effekt p√• funktionsf√∂rm√•gan (GRADE ÔÉÖÔ??Ô??Ô??).\r\nKomplikationer\r\nL√•ngtidsbehandling med MCS f√∂rsv√•ras av flera olika komplikationer som pumpdysfunktion,\r\ninfektioner (20 ‚Äì 60 \%), bl√∂dningar (15 ‚Äì 30 \%), tromboemboliska h√§ndelser (5 ‚Äì 25 \%)\r\nh√∂gerkammarsvikt (10 ‚Äì 40 \%). Parallellt med f√∂rb√§ttrad teknik har frekvensen av olika bieffekter\r\nstadigt sjunkit under senare √•r.\r\nEtiska aspekter:\r\nEtt behandlingsprogram med MCS har ett antal etiska konsekvenser. Effekten p√• individens\r\nsj√§lvk√§nsla och sj√§lvbild varierar sannolikt mellan olika patienter och de kan p√•verkas s√•v√§l\r\npositivt som negativt. Patienten kommer inte vara helt obereoende av andra utan f√∂rblir till viss\r\ndel beroende av hj√§lp fr√•n familjemedlemmar och h√§lso- och sjukv√•rdspersonal. Den fysiska\r\nintegriteten p√•verkas. Om inte nya ekonomiska resurser tillf√∂rs h√§lso- och sjukv√•rden √§r risken\r\nstor att ett program med permanent MCS till patienter med terminal hj√§rtsvikt kommer att ta\r\nresurser f√∂r andra patientkategorier.\r\nEkonomiska aspekter:\r\nKostnaden f√∂r den idag mest anv√§nda CF-LVAD, HeartMate II, √§r 750 000 SEK. Ytterligare 125\r\n000 SEK tillkommer f√∂r n√∂dv√§ndiga tillbeh√∂r. P√• Sahlgrenska Universitetssjukhuset har √•tta\r\npatienter f√•tt en HeartMate II inplanterad som MCS f√∂r l√§ngre √§n 12 m√•nader under √•ren 2010-\r\n2012. Den genomsnittliga behandlingskostnaden per patient f√∂r det f√∂rsta √•ret var cirka 1,5\r\nmiljoner SEK.\r\nSlutsatser:\r\nMekaniskt v√§nsterkammarst√∂d som permanent behandling kan f√∂rl√§nga √∂verlevnaden hos\r\npatienter med terminal hj√§rtsvikt och minska 1-√•rsd√∂dligheten med cirka 30 \% . Behandlingen √§r\r\nf√∂renad med h√∂g kostnad och f√∂rsv√•ras av flera allvarliga komplikationer. Under senare √•r har\r\nkostnaderna minskat och √§ven komplikationsfrekvensen har sjunkit.\r\n HTA-report: LVAD in heart failure 9(22)\r\nAbbreviations\r\nACE Angiotensin converting enzyme\r\nBIVAD Biventricular assist device\r\nBTT Bridge to transplantation\r\nCF Continuous flow\r\nCPET Cardiopulmonary exercise test\r\nCRT Resynchronization therapy\r\nDT\r\nICD\r\nDestination therapy\r\nImplantable cardioverter defibrillator\r\nLVAD Left ventricular assisted device\r\nMCS Mechanical circulatory support\r\nNYHA New York Heart Association\r\nOMT Optimal medical treatment\r\nPF Pulsatile flow\r\nQALY Quality-adjusted life years\r\nQoL Quality of life\r\nRCT Randomised controlled trial\r\nRVAD Right ventricular assist device\r\nRVF Right ventricular failure\r\nVAD Ventricular assist device\r\n HTA-report: LVAD in heart failure 10(22)\r\nThe Patient Category and the Present Treatment\r\nHeart failure and degree of severity\r\nHeart failure is a clinical syndrome attributable to disturbances in cardiac function. The\r\ndysfunctions may have various underlying causes. The heart failure syndrome is multifaceted and\r\nnot readily defined. Below are three definitions that describe heart failure from different\r\nviewpoints.\r\n1. Acute and hemodynamic viewpoint\r\n- a pathological state in which an abnormality of cardiac function is responsible for failure of\r\nthe heart to pump blood at a rate commensurate with the requirements of the metabolizing\r\ntissues, or to do so only from an elevated filling pressure. (Braunwald E. 1997)\r\n2. Chronic and neurohumoral viewpoint\r\n- a clinical syndrome characterized by abnormalities of left ventricular function and\r\nneurohormonal regulation, which are accompanied by effort intolerance, fluid retention and\r\nreduced longevity. (Packer M. 1992)\r\n3. Clinical and diagnostic viewpoint\r\n- a clinical syndrome in which patients have the following features: symptoms typical of\r\nheart failure and signs typical of heart failure and objective signs of a structural or functional\r\nabnormality of the heart at rest. (European Society of Cardiology 1995)\r\nThe syndrome is characterized by inability of the heart to maintain adequate blood flow and/or\r\nnormal filling pressures during physical activity or in later stages also at rest. A number of\r\nneurohumoral compensatory mechanisms are activated in order to maintain the circulation. Over\r\ntime they have a deleterious effect on the heart with further deterioration of cardiac function. A\r\nvicious cycle arises. If untreated this leads to a continuous decline of cardiac function and\r\nprogressive worsening of the symptoms. Clinical symptoms consist mainly of fatigue,\r\nbreathlessness and fluid retention. This frequently leads to hospitalisation. Quality of life is\r\nimpaired and mortality is high.\r\nDuring work up of a heart failure patient, it is important to evaluate the underlying cause of\r\ncardiac failure, the degree of cardiac dysfunction and the functional capacity of the patient.\r\nPharmacologic treatment is aimed at reducing the deleterious effects of neurohumoral activation\r\nand to alleviate fluid retention. In selected patients a pacemaker system may improve left\r\nventricular dyssynchrony and an implantable defibrillator can prevent sudden cardiac death. In\r\nterminal heart failure, mechanical circulatory assist devices or heart transplantation can be an\r\nalternative to palliative care.\r\nHeart failure is a serious condition with an increased\r\nÔÇ∑ risk of premature death\r\nÔÇ∑ risk of permanent illness or damage, or reduced quality of life\r\nÔÇ∑ risk of disability and impaired health-related quality of life\r\nThe prevalence and incidence of heart failure\r\nIn a recently published report the prevalence of chronic heart failure in Sweden was estimated to\r\n2 \% (Zarinkoub R et al. 2013). The mean age of heart failure patients was 77 years, and more than\r\n90 \% of the patients were 60 years or older. The estimated incidence rate of chronic heart failure\r\nwas 3.8/1000. The 5-year survival rate from first diagnosis was 48 \%, which is considerably\r\nlower than in the general Swedish population matched for age and sex (95\%).\r\nIn other community-based cohorts the annual survival rate in patients diagnosed with mild heart\r\nfailure (NYHA I-II) has been shown to be around 95 \%, whereas the 1-year survival rate for those\r\ndiagnosed with severe heart failure (NYHA IV) has been reported to below 50 \%. \r\n HTA-report: LVAD in heart failure 11(22)\r\nPresent treatment of heart failure\r\nThe goal of treatment is to relieve symptoms, optimize cardiac function and increase longevity.\r\nThis can be achieved in most cases with the currently available treatment alternatives. They\r\ninclude different pharmacological, electric, mechanical and surgical options. On the other hand, it\r\nis also important to identify patients in the terminal phase of the disease, who are not suitable for\r\nadvanced treatment with devices, mechanical pumps or heart transplantation. These patients\r\nshould receive supportive and palliative care to provide relief from symptoms and other distress\r\nassociated with end-stage heart failure.\r\nPharmacological intervention is the cornerstone of heart failure treatment. It is well documented\r\nthat neurohumoral blockade of the sympathetic nervous system and the renin-angotensinaldosteron-system\r\nreduce symptoms, improve cardiac function and increase survival. Four\r\ndifferent pharmaceutical groups are currently recommended for treatment of heart failure; beta\r\nblockers, ACE-inhibitors, angiotensin II receptor blockers, and mineralcorticoid receptor\r\nantagonists. Diuretics are frequently used to control fluid retention. Other drugs that sometimes\r\nare used are ivabradin (sinus node inhibitor), digoxin (inotropic agent), hydralazine and\r\nisosorbiddinitrate (vasodilators), and anticoagulant agents (thromboembolic prophylaxis).\r\nAbout one third of all patients with heart failure die suddenly, mainly due to a ventricular\r\ntachyarrhythmia. The implantation of a cardioverter defibrillator (ICD) reduces mortality in\r\npatients with moderate to severe systolic heart failure. One third of patients with heart failure has\r\nan intraventricular conduction disturbance that can cause left ventricular dyssynchrony with less\r\nefficient ventricular emptying and, often, mitral regurgitation. Cardiac resynchronization therapy\r\n(CRT) can improve cardiac function in these patients, relieve symptoms, improve functional\r\ncapacity, and improve survival. Currently, patients who fulfil the criteria for CRT treatment most\r\noften also receive an ICD.\r\nAlso surgical interventions may be indicated for specific underlying or contributing causes of\r\nheart failure. These include revascularization in patients with ischemic heart disease, valvular\r\nsurgery in patients with valvular disease, and left ventricular reconstruction in patients with\r\nextensive scarring and remodelling of the left ventricle after myocardial infarction. For a small\r\nminority of heart failure patients heart transplantation may be indicated. The indication for heart\r\ntransplantation is terminal heart failure with severe symptoms, poor prognosis, and no remaining\r\ntreatment alternatives. However, due to organ shortage this treatment is only available to a limited\r\nnumber of patients (approximately 50 annually in Sweden).\r\nContraindications to a cardiac transplant are high pulmonary vascular resistance, active infection,\r\nwidespread atherosclerotic disease, drug abuse, malignant disease, recent thromboembolism,\r\nsignificant renal or liver disease, or other serious non-reversible co-morbidies. At Sahlgrenska\r\nUniversity Hospital 20-30 heart transplantations are performed each year including approximately\r\n5-7 recepients from the Region V√§stra G√∂taland.\r\nSelected patients with progressive heart failure in whom pharmacological and/or\r\nresynchronisation therapy are insufficient can be treated with mechanical circulatory support\r\n(MCS). The goal of MCS is to support the circulation until transplantation (bridge to\r\ntransplantation) or until the heart recovers (bridge to recovery), or to offer a permanent treatment\r\noption, which has been called destination therapy (DT). Presently, DT is not available as a\r\ntreatment alternative in routine clinical practice in Region V√§stra G√∂taland, Sweden. In countries\r\nsuch as USA and Germany the number of patients who receive MCS as DT has now exceeded\r\nthat of patients treated with heart transplantation. \r\n HTA-report: LVAD in heart failure 12(22)\r\nNumbers of patients per year who are candidates for LVAD as destination therapy\r\nPotential candidates for DT are patients with end-stage heart failure who are not considered\r\nsuitable for heart transplantation due to advanced age and/or severe co-morbidities.\r\nExamples of customary criteria for identification of end-stage heart failure are the following:\r\nÔÇ∑ Left ventricular ejection fraction ‚â§ 35\%\r\nÔÇ∑ Max VO2 ‚â§ 14 ml/kg/min on cardiopulmonary exercise test (CPET)\r\nÔÇ∑ 6 minute walking distance ‚â§ 300 m\r\nÔÇ∑ More than one hospitalisation during 6 months\r\nÔÇ∑ Intolerance of ACE-inhibitors and/or beta-blockers\r\nÔÇ∑ Low systolic blood pressure (< 90 mmHg)\r\nÔÇ∑ Inotrope dependence in-hospital and difficult to wean\r\nÔÇ∑ Worsening renal and/or liver function\r\nÔÇ∑ Worsening right ventricular function.\r\nApart from advanced age, there are several co-morbidities that render heart failure patients\r\nineligible for heart transplantation, but not for treatment with destination therapy: Examples of\r\nsuch co-morbidities are: BMI ‚â• 30 kg/m2\r\n, increased pulmonary vascular resistance, cancer\r\ntreatment within 5 years, and reduced pulmonary, renal and/or liver function. However, only a\r\nsmall fraction of all patients with end-stage heart failure should be considered candidates for DT.\r\nFor example, it is vital that potential DT candidates are emotionally stable and able to comply\r\nwith MCS treatment. Absolute contraindications for MCS include active infection, widespread\r\natherosclerotic disease, terminal disease other than heart failure, dialysis, severe liver cirrhosis,\r\nalcohol or drug abuse, and untreated psychiatric disease.\r\nThus, identification of potential candidates for DT is a highly selective process. It is estimated\r\nthat around 5-10 patients would fulfil the criteria for DT each year in Region V√§stra G√∂taland.\r\nThe normal pathway of patients with terminal heart failure through the health care\r\nsystem\r\nPatients who are considered candidates for heart transplantation undergo a thorough in-hospital\r\nwork-up before they are discussed at a multidisciplinary board. The board consists of\r\ncardiologists, thoracic surgeons, thoracic anaesthesiologists, heart failure nurses and patient\r\ncoordinators. The work-up includes extensive laboratory investigations and a thorough\r\ninvestigation of cardiac function with echocardiography and cardiac catheterisation. Further\r\nfunctional capacity is evaluated with CPET and/or 6-minute walking test. Renal function is\r\nassessed by glomerular filtration rate and pulmonary function is estimated by spirometry. An\r\nodontologist evaluates the dental status.\r\nThe patients who are accepted for transplantation ofte receive MCS as bridge to transplantation.\r\nPatients that are declined heart transplantation due to advanced age or comorbidities continue to\r\nreceive conventional heart failure treatment, often combined with supportive and/or palliative\r\ncare.\r\nThe work-up and decision process for DT is very similar to that used for heart transplantation. \r\n HTA-report: LVAD in heart failure 13(22)\r\nThe New Health Technology ‚Äì Left Ventricular Assisted Device\r\nDescription of left ventricular assisted device\r\nA ventricular assist device (VAD) is a mechanical circulatory device that is used to partially, or\r\ncompletely, replace the function of a failing heart. It takes blood from a ventricle of the heart and\r\npumps it to the circulation, and thereby secures perfusion of vital organs. A VAD can support the\r\nleft ventricle (LVAD), the right ventricle (RVAD), or both ventricles (BIVAD).\r\nA VAD consists of a small pump, a tube that carries blood from a heart ventricle into the pump,\r\nand another tube that carries the blood from the pump to either the pulmonary artery (RVAD) or\r\nthe aorta (LVAD). It also has a driveline that connects the pump to a power source through a\r\ncontrol unit. The figures illustrate a LVAD (Courtesy of Thoratec corporation).\r\nVADs can be divided into two main categories. Firstly, pulsatile flow (PF) pumps that mimic the\r\nnatural pulsing action of the heart (first generation VADs), and secondly, continuous flow (CF)\r\ndevices that generate continuous blood flow with either a centrifugal or an axial pump (second\r\ngeneration VADs). Patients treated with a VAD require life-long anticoagulation therapy in order\r\nto prevent thrombus formation and thromboembolic complications.\r\nThe group‚Äôs understanding of left ventricular assist devices as destination therapy in\r\npatients with terminal heart failure\r\nThe use of LVADs for DT has steadily increased, especially in countries such as Germany,\r\nFrance, Belgium, Switzerland, Austria, Canada and USA. In 2010 there were 79 destinationtherapy\r\ncentres in USA certified to perform implantation of LVADs. According to the\r\nINTERMACS registry (only including US patients) approximately 1000 patients received LVAD\r\nas DT-therapy in 2012, and another 800 patients received LVAD as bridge-to-transplantation\r\n(BTT).\r\nSome patients that initially have been regarded as excellent BTT candidates will eventually not\r\nbecome eligible for heart transplantation due to progression of co-morbidities or new\r\ncomplications. On the other hand, some patients being identified, as DT-candidates will after\r\nLVAD implantations improve in such a way that they become suitable for a cardiac\r\ntransplantation. \r\n HTA-report: LVAD in heart failure 14(22)\r\nIn 2012 approximately 700 patients had an LVAD implanted in Germany, and only 300 heart\r\ntransplantations were performed. This means that most patients with terminal heart failure receive\r\na LVAD initially, and later it is decided whether they should be listed for transplantation or\r\nremain on DT.\r\nThere is no Swedish VAD registry, but there is some information available on DT in Sweden\r\nfrom a company registry (Vingmed AB, the sales representative for Thoratec and the Heart Mate\r\nII). In total, 25 patients have received a LVAD (Heart Mate II) for DT in Sweden between 2005\r\nand 2013 (survival range 2 - 2216 days, mean age 63 years, 22 males, 18 patients had ischemic\r\ncardiomyopathy). Among these patients, six (24 \%) died within 90 days. The remaining 19\r\npatients have survived for a mean of 815 days (with 9 patients still alive). Six of the patients (24\r\n\%) patients eventually underwent heart transplantation, again underlining that DT patients on\r\nLVAD may improve to such an extent that they become suitable candidates for transplantation. It\r\nseems necessary to have a DT program in order to give all patients a chance to become\r\ntransplanted, even if the majority will remain on LVAD for the rest of their lives. Thus, DTtherapy\r\nas an entity and definition is slowly becoming obsolete. If permanent LVAD treatment is\r\nnot available, patients with transplant precluding comorbidities that might resolve during\r\nmechanical support will not get an opportunity for transplantation.\r\nDuring the last decade, the LVAD technology has progressed to become standard therapy in\r\nsome medical centres. It is important that all centres that provide DT use best-practice guidelines\r\nto maintain outcomes that are comparable to those of existing centres of excellence.\r\nThe ethical concerns raised by DT will require extensive information to patients and their\r\nfamilies, and also a detailed DT program that will meet the needs of patients and other family\r\nmembers. Examples of prerequisite conditions before introducing a program with destination\r\ntherapy include:\r\n1. Participation of a multidisciplinary care team, including palliative care specialists\r\n2. Adopting a concise plan of care for anticipated device-related complications\r\n3. Planning for anticipated end-of-life care and timing of device deactivation\r\n HTA-report: LVAD in heart failure 15(22)\r\nThe Central Question at Issue\r\nDoes mechanical circulatory support with left ventricular assist devices (LVAD) reduce\r\nmorbidity, improve quality of life, and prolong survival in patients with end-stage heart failure\r\nnot eligible for heart transplantation, in comparison to optimal medical treatment?\r\nPICO\r\nP= Patients, I= Intervention, C= Comparison, O=Outcome\r\nPICO 1\r\nP = Patients with end-stage left ventricular heart failure despite optimal medical treatment\r\nI = Left ventricular assist device with pulsatile flow (PF-LVAD)\r\nheart transplant\r\nC = Optimal medical treatment (OMT)\r\nO = Survival, quality of life (QoL), functional capacity (NYHA classification, 6 minute walk\r\ntest, exercise test) and biomarkers of heart failure. Complications such as infections,\r\nhaemorrhages, thromboembolic events and neuropsychological functions\r\nPICO 2\r\nP = Patients with terminal left ventricular heart failure despite optimal medical treatment\r\nI = Left ventricular assist device with continuous flow (CF-LVAD)\r\nC = Left ventricular assist device with pulsatile flow (PF-LVAD)\r\nO = Survival, quality of life, functional capacity (NYHA classification, 6 minute walk test,\r\nexercise test) and biomarkers of heart failure.\r\nComplications such as infections, haemorrhages, thromboembolic events and\r\nneuropsychological functions\r\nheart transplant\r\n HTA-report: LVAD in heart failure 16(22)\r\nReview of the Quality of Evidence\r\nSearch strategy, study selection and references ‚Äì appendix 1\r\nDuring February 2013 two librarians (TS, AL) performed systematic searches in\r\nMedline, PubMed, Embase, the Cochrane Library and a number of HTA-databases.\r\nReference lists of relevant articles were also scrutinised for additional references.\r\nSearch strategies, eligibility criteria and a graphic presentation of the selection\r\nprocess are accounted for in appendix 1. The librarians conducted the literature\r\nsearches, selected studies, and independently assessed the obtained abstracts and\r\nmade a first selection of full-text articles for inclusion or exclusion. After reading\r\nthe articles in full text they made a second selection of articles. Any disagreements\r\nwere resolved in consensus. The articles that remained were sent to the other\r\nparticipants in the HTA group, who read the articles independently of one another,\r\nand then decided in a consensus meeting which articles that should be included.\r\nThe literature search identified a total of 1231 articles (after removal of duplicates).\r\nThe librarians then excluded 1095 articles after reading their abstracts. Another 136\r\narticles were excluded by the librarians after reading the articles in full text. The\r\nremaining 56 articles were sent to the group, and 26 of them were finally included\r\nin the report. There were two randomised controlled trials (RCT, four publications)\r\nand three non-randomised controlled studies (three publications). Twelve were case\r\nseries, five were systematic reviews, and two were health economy analyses. The\r\ncontrolled studies have been critically appraised using modified checklists from the\r\nSwedish Council on Health Technology Assessment regarding randomized\r\ncontrolled trials and cohort studies.\r\nThe present knowledge of left ventricular assist devices as destination therapy\r\nin patients with terminal heart failure\r\nPICO 1 ‚Äì comparison of PF-LVAD with OMT\r\nTwo HTA reports have concluded that LVAD with pulsatile flow improves survival\r\nand quality of life. One was published in 2005 by the NIHR Coordinating Centre for\r\nHealth Technology Assessment (NCCHTA) in Southampton, UK (Clegg AJ et al.\r\n2005), and the other in 2007 by the German Agency for HTA of German Institute of\r\nMedical Documentation and Information (Angermayr L et al. 2007).\r\nThe systematic literature search identified one randomised controlled trial (RCT)\r\nand one non-randomised controlled study that have studied the effects of PF-LVAD\r\nin comparison to OMT in patients with end-stage heart failure. In the RCT 61\r\npatients were treated with OMT and 68 patients were treated with the pulsatile\r\nLVAD HeartMate I. The trial had no major problems concerning directness, study\r\nlimitations or precision. The non-randomised study was smaller and the two study\r\ngroups were not balanced with regard to socio-economic status. The patients in the\r\ncontrol group consisted of patients who did not choose, or did not have the financial\r\nresources, to undergo LVAD implantation.\r\n HTA-report: LVAD in heart failure 17(22)\r\nMortality (Appendix 4a)\r\nThe RCT reported a significantly (p< 0.01) higher one-year survival in the PFLVAD\r\ngroup (52 \%) compared to the OMT group (23 \%). The two-year survival\r\nrates were 23 \%, and 8 \% respectively (ns). In the non-randomised study, the\r\ncorresponding 1-year survival rates were 27 \% and 11\% (p>0.05).\r\nConclusion: Pulsatile LVAD as destination therapy probably increases survival in\r\ncomparison with OMT in patients with end-stage left ventricular heart failure.\r\nModerate quality of evidence (GRADE ÔÉÖÔÉÖÔÉÖÔ??).\r\nQuality of life (Appendix 4b)\r\nThe RCT analysed quality of life after one year using three different questionnaires.\r\nDue to the high mortality rate QoL-scores were only available in six OMT and 23\r\nPF-LVAD patients. The SF-36 Emotional role and Beck Depression Inventory\r\nscores were significantly better in the PF-LVAD group, but no difference between\r\nthe study groups was seen in Minnesota Living with heart Failure scores.\r\nConclusion: It is uncertain whether PF-LVAD improves the quality of life in\r\ncomparison with OMT in patients with end-stage left ventricular heart failure.\r\nVery low quality of evidence (GRADE ÔÉÖÔ??Ô??Ô??)\r\nFunctional capacity (Appendix 4c)\r\nBoth the RCT and the non-randomised study analysed functional capacity after oneyear\r\nfollow-up. Due to the high mortality rate only six OMT-patients and 23\r\nLVAD-patients were tested in the RCT. Both the ability to ‚Äúwalk one block without\r\nany physical limitation‚Ä? and SF-36 physical function score were significantly better\r\nin the PF-LVAD group than in the OMT group. In the non-randomised study 11 of\r\n18 patients in the OMT and 22 of 37 patients in the PF-LVAD group were evaluated\r\nby the NYHA classification. At the last assessment all patients in the OMT were\r\nstill in NYHA class IV, while 85 \% of the patients in the PF-LVAD group had\r\nimproved to NYHA class I-II.\r\nConclusion: PF-LVAD may improve the functional capacity in comparison with\r\nOMT in patients with end-stage left ventricular heart failure.\r\nLow quality of evidence (GRADE ÔÉÖÔÉÖÔ??Ô??Ô??)\r\nPICO 2 ‚Äì comparison of CF-LVAD with PF-LVAD\r\nTwo published reviews have assessed the effects of the newer continuous flow\r\ndevices (CF-LVAD) in patients with end-stage heart failure. One is a systematic\r\nreview from the Department of Veteran Affairs, US, published in 2011 (Rector TS\r\net al. 2012). It concludes that one single study provides moderate evidence that the\r\nuse of the HeartMate II LVAD increases patient survival, with fewer complications\r\nand fewer hospitalizations compared to the older pulsatile flow LVAD HeartMate I.\r\nThe other review is from Quebec (INESS) published in 2012 (Sas G et al. 2012). It\r\nconcludes that CF-LVAD can be considered a clinically effective therapeutic option\r\ncompared to optimal medical treatment for appropriate patients in both BTT and DT\r\npatients.\r\nThe systematic literature search identified one RCT and two non-randomised\r\ncontrolled studies that have studied the effects of PF-LVAD in comparison to CFLVAD\r\nin patients with end-stage heart failure. In the RCT the patients were\r\nrandomised in a 2:1 ratio. Thus, 134 patients received a continuous flow HeartMate\r\nII and 66 patients received a pulsatile flow HeartMate I. The study had some \r\n HTA-report: LVAD in heart failure 18(22)\r\nproblems with directness and precision (see Appendix 7, SoF table). The two nonrandomised\r\ntrials had major problems, as most of the pulsatile LVADs were\r\nimplanted some years before the continuous flow devices came in use. Thus, the\r\npatient study groups with PF-LVADs must be regarded as historical controls.\r\nMortality (Appendix 5a)\r\nThe RCT reported a one-year survival of 68 \% in the CF-LVAD group and 55 \% in\r\nthe PF-LVAD group. The survival was significantly better ( p< 0.01) in the CFLVAD\r\ngroup after two years with a survival rate of 58 \% in comparison to 24 \% in\r\nthe PF-LVAD group. Both the non-randomised studies reported significantly higher\r\ntwo-year survival rates in the patients who received a CF-LVAD.\r\nConclusion: Continuous flow LVAD as destination therapy probably increases\r\nsurvival in patients with end-stage heart failure in comparison with pulsatile flow\r\nLVAD.\r\nModerate quality of evidence (GRADE ÔÉÖÔÉÖÔÉÖÔ??).\r\nQuality of life (Appendix 5b)\r\nOnly the RCT analysed the quality of life. This was done after one year and two\r\nyears follow-up using two different questionnaires. However, the small numbers of\r\npatients at the two-year follow-up did not allow any meaningful analyses. QoL\r\nimproved in both LVAD groups in comparison to baseline. According to Minnesota\r\nLiving with Heart Failure questionnaire, QoL was significantly better in the CFLVAD\r\ngroup compared to the PF-LVAD group after one year, whereas the\r\ndifference in the Kansas City Cardiomyopathy questionnaire did not reach statistical\r\nsignificance (p = 0.06).\r\nConclusion: PF-LVAD may improve the quality of life in patients with end-stage\r\nleft ventricular heart failure in comparison with PF-LVAD.\r\nLow quality of evidence (GRADE ÔÉÖÔÉÖÔ??Ô??)\r\nFunctional capacity (Appendix 5c)\r\nOnly the RCT analysed functional capacity. As for the QoL analyses, only the data\r\nat 12-month follow-up allowed a meaningful comparison. Both study groups\r\nexperienced early, and sustained, improvement of functional capacity. However,\r\nthere was no significant difference between the two groups.\r\nConclusion: It is uncertain whether CF-LVAD and PF-LVAD differ in their effects\r\non functional capacity.\r\nVery low quality of evidence (GRADE ÔÉÖÔ??Ô??Ô??).\r\nComplications (Appendix 6)\r\nLong-term MCS is hampered by several complications such as device malfunction,\r\ninfections, bleeding, thromboembolic events and right ventricular failure (RVF).\r\nThe rate of adverse events has steadily declined with improved techniques (second\r\ngeneration LVAD vs first generation).\r\nInfections are a significant problem. They often occur at the driveline exit site. The\r\nreported incidence is up to 40 \% per year (events/patient/year). Sepsis is also\r\ncommon with reported incidence rates varying from 20 \% to 60 \% in different\r\nstudies. Infections that involve the pump itself are uncommon, but are serious since\r\nlong-term eradication is nearly impossible.\r\n HTA-report: LVAD in heart failure 19(22)\r\nBleeding events are common. Perioperative bleeding occurs, in particular in patients\r\nwith previous cardiac operations and/or coagulopathy related to hepatic dysfunction.\r\nRe-exploration due to a post-operative bleeding has been reported to be required in\r\n15 ‚Äì 30 \%. Bleeding complications during long-term follow-up are also frequent, in\r\nparticular gastrointestinal bleeding, with incidence rates up to 50 \%\r\n(events/patient/year).\r\nPatients with LVADs may also suffer thromboembolic complications. The reported\r\nincidence of ischemic stroke varies between 5 - 25 \%. Pump thrombus may occur,\r\nand sometimes necessitates pump replacement if aggressive anticoagulation or\r\nthrombolytic therapies are not successful.\r\nIt is essential that the right ventricular function is adequate for an LVAD to function\r\nnormally. Right ventricular failure occurs in10 - 40 \% of patients who receive\r\nLVAD as bridge-to-transplantation.. The incidence of RVF in adequately selected\r\npatients for DT is not known. Treatment includes optimization of the right\r\nventricular function, management of pulmonary vasoconstriction, and in some cases\r\ntemporary support with a right ventricular assist device.\r\nOngoing research?\r\nA search in the ClinicalTrials database (www.clinicaltrials.gov) July 4, 2013, using the\r\nsearch terms (heart-assist device OR left ventricular assist device OR left ventricular\r\nassist system OR ventricular assist device OR VAD OR LVAD OR LVAS) AND\r\n(destination OR permanent OR non-transplant OR long-term OR ineligible OR \"not\r\nassist support devices\r\neligible\" OR \"not candidate\" OR non-candidate) identified 33 studies with regard to\r\nLVADs. Five studies were relevant for the present questions at issue.\r\nTwo studies will compare the CF-LVAD HeartMate II with optimal medical therapy.\r\nBoth of them are being performed in the USA. One of them is an RCT (REVIVE-IT), and\r\nit is currently recruiting patients. The estimated completion date is December 2016. The\r\nother study one is a non-randomised study that is ongoing. Its estimated completion date\r\nis December 2015.\r\nAnother two RCTs are ongoing. They compare either the LVADs Jarvik 2000 with Heart\r\nMate II (estimated completion date December 2016), or the HeartWear LVAD with ‚Äúany\r\nother FDA approved LVAD‚Ä? (estimated completion date May 2017). Both are being\r\nperformed in the USA. The former is still recruiting patients whereas the other is not.\r\nA fifth study is ongoing in Belgium. It is a non-randomised study that will compare the\r\nefficacy of HeartMate II with historical controls.\r\nWhich medical societies or health authorities recommend left ventricular assist devices as\r\ndestination therapy in patients with terminal heart failure?\r\nIn the European Society of Cardiology Guidelines for the diagnosis and treatment of acute and\r\nchronic heart failure 2012 DT it is recommended for highly selected patients, who have end-stage\r\nheart failure despite optimal pharmacological and device therapy, and who are not suitable for\r\nheart transplantation, but are expected to survive over one year with good functional status, to\r\nimprove symptoms, and reduce the risk of heart failure hospitalization and of premature death\r\n(Eur Soc Cardiol. 2012) \r\n HTA-report: LVAD in heart failure 20(22)\r\nThe 2013 ACCF/ American Heart Association Guidelines for the Management of Heart Failure\r\nalso recommended DT with durable MCS to prolong survival for carefully selected patients with\r\nstage D heart failure with reduced ejection fraction (ACCF/AHA 2013).\r\nIn the Swedish National Guidelines for Cardiovascular Diseases from 2008 it is concluded that\r\nDT may improve survival, functional capacity and quality of life in patients with advanced heart\r\nfailure (NYHA IIIB-IV) that receive OMT and are not eligible for heart transplantation\r\n(Socialstyrelsen 2008). However, the ratio of cost to quality-adjusted life-year (QALY) was\r\nconsidered to be very high. In these guidelines, which are those available in Sweden today, DT is\r\nnot recommended for routine use. Instead it is advocated that further results from on-going\r\nstudies should be awaited.\r\nEthical Aspects\r\nSee Appendix 8\r\nOrganisation\r\nWhen can left ventricular assist device for destination therapy be put into practice at the\r\nhospital?\r\nImmediately.\r\nIs left ventricular assist device for destination therapy used in other hospitals in Region\r\nV√§stra G√∂taland, Sweden?\r\nNo. At the present, DT is not available for patients with end-stage heart failure in Region V√§stra\r\nG√∂taland. In the Stockholm Region there is currently a treatment program with DT, and up until\r\nnow a total of 15-20 patients have received this treatment (Dr LH Lund, Karolinska University\r\nHospital, Stockholm, Sweden, personal communication October 2013).\r\nWill there be any consequences of left ventricular assist device for destination therapy for\r\nthe personnel?\r\nCurrently, mechanical circulatory support systems are frequently utilized as BTT, and the\r\nhospital personnel are already familiar with the treatment. Introduction of DT would lead to an\r\nincreased number of patients with long-term follow-up.\r\nWill there be any consequences for other clinics or supporting functions at the hospital or\r\nin the whole Region V√§stra G√∂taland?\r\nYes. Initial, follow-up of the patients will take place at the outpatient clinic of the Department\r\nof Cardiology Sahlgrenska Hospital. Later on follow-up visits will also be necessary at the local\r\nhospitals. However, there will only be a few patients (less than 10) requiring follow-up during\r\nthe first years after the initiation of a DT program. \r\n HTA-report: LVAD in heart failure 21(22)\r\nEconomy Aspects\r\nPresent costs of a continuous flow left ventricular assist device\r\nThe current cost for the CF-LVAD HeartMate II implant kit is 750,000 SEK\r\n(ÔÇª82,000 ‚Ç¨), and for accessories 125,000 SEK (ÔÇª14 000 ‚Ç¨).\r\nDuring 2010-2012, 8 patients had an implanted HeartMate II as mechanical circulatory support\r\nfor 12 months or longer. The average cost for the first year was about 1.5 million SEK\r\n(including the cost of the implant kit and accessories) ranging between 1.4-2.7 million SEK\r\n(ÔÇª153,000 ‚Äì 295,000 ‚Ç¨). The cost was related to the number of in-hospital days, especially the\r\nnumber of days in the intensive care unit. The average length of hospital stay was 50.5 days\r\n(range 29-95).\r\nAs a comparison, three patients with terminal heart failure (NYHA class III-IV) who have been\r\nfollowed for more than one year with OMT were identified. The costs for these patients\r\nbetween June 2011 to May 2012, i.e. one year, were 132,000 SEK (ÔÇª14,000 ‚Ç¨) , 759,000 SEK\r\n(ÔÇª144,000 ‚Ç¨) and 1,909,000 SEK (ÔÇª208,000 ‚Ç¨), respectively. Also in these cases the yearly\r\ncosts was directly related to the length of hospital stay (range: 17- 134 days).\r\nIn the calculations of the costs for CF-LVAD and OMT above, the costs of home care are not\r\nincluded (due to different management systems).\r\nIn 2010, the average cost for heart transplantation was approximately 1.25 million SEK\r\n(ÔÇª136,000 ‚Ç¨). This includes only the surgical procedure and the postoperative hospital stay. The\r\ncosts of follow-up and later hospitalisations are not included.\r\nExpected costs of left ventricular assist device in patients with terminal heart failure\r\nSee 9a.\r\nTotal change of cost of left ventricular assist device in patients with terminal heart failure\r\nThe cost of 10 patients treated with LVAD (see 2d) during the first year is estimated to be about\r\n15 million SEK. Assuming that the corresponding cost for a patient treated with OMT is\r\n750,000 SEK, the change in cost will be an increase of 7.5 million SEK.\r\nSince patients with LVAD are expected to live longer this will add further increments in the\r\ntotal costs during the following years. It is difficult to estimate this additional cost.\r\nCan the use of left ventricular assist device in patients with terminal heart failure be\r\nadopted and used within the present clinic budget?\r\nNo.\r\nAre there any available analyses of health economy? Cost advantages or disadvantages?\r\nThere is no Swedish cost-effectiveness analysis.\r\nIn the German HTA report (Angermayer 2007), which was based predominately on studies of\r\nthe first generation LVADs, i.e. PF-LVADS, the conclusion was that ‚Äúthe incremental costs per\r\nquality-adjusted life years (QALYs) may be between 200 000 and 600 000 ‚Ç¨ for DT‚Ä?. Similar \r\n HTA-report: LVAD in heart failure 22(22)\r\nconclusions were made in a British expert review from 2008 that could identify four published\r\ncost-effectiveness studies (Hutchinson 2008). However, they also pointed out that the\r\nmethodological quality in the majority of the studies was poor, as was their generalizability.\r\nA Canadian HTA report published in 2012 concluded that the cost-effectiveness of Heart Mate\r\nII was ‚Äúunfavourable‚Ä? regardless of the initial indication (Sas 2012). However, the conclusions\r\nwere based predominantly on experiences of HeartMate II and mostly as BTT. Since these\r\npatients relatively soon get a transplant, the real cost benefit of the LVAD is therefore\r\nunderestimated when data are extrapolated to the DT indication.\r\nThere have been no studies that directly have compared CF-LVADS with OMT. Rogers et al.\r\nused data from the REMATCH trial and the Heart Mate II trial to indirectly estimate the costeffectiveness\r\nof using the CF-LVAD Heart Mate II (Rogers 2012). Compared with medical\r\nmanagement the CF-LVAD had higher 5-year costs ($360 407 versus $62 856) and QALYs\r\n(1.87 vs 0.37). The incremental cost-effectiveness ratio of the CF-LVAD was estimated to be\r\n$198 184 per QALY (this corresponds to about 1.2 million SEK/QALY).\r\nUnanswered Questions\r\nImportant gaps in scientific knowledge\r\nThere are no published RCTs that have compared the outcomes of modern CF-LVADs with OMT\r\nwith regard to survival, functional capacity, or quality of life. Such a trial would presently be of\r\ngreat interest, since pharmacological treatment, resynchronization therapy, and the overall\r\nmanagement of heart failure have improved during the last decade (after the publication of the\r\nRCT that initially compared PF-LVAD with OMT). It is of interest to point out that such a trial is\r\npresently considered unethical in the USA.\r\nIs there any interest in your own clinic/research group/organisation to start studies/trials\r\nwithin the research field at issue?\r\nYes. We are interested in starting a prospective, randomized multicentre trial in Sweden\r\nevaluating the HeartMate II¬Æ LVAD versus OMT in patients with severe heart failure (NYHA\r\nIIIb-IV) that are not eligible for heart transplantation. In such a study we would aim to include\r\n100-120 patients and randomize them to HM II or OMT in a 1:1 ratio. The primary outcome\r\nwould be a composite endpoint of survival, freedom from debilitating stroke and improved\r\nfunctional capacity. Patient recruitment would be expected to take 18 months and each\r\nincluded patient would be followed for 18 months.\r\nThe Departments of Cardiology and Thoracic Surgery at all Swedish University Hospitals have\r\nshown interest in such a study and are willing to participate. A reference group with\r\nparticipants from all university hospitals has been engaged to work on a study protocol. The\r\ninitial response from the LVAD industry (Thoratec) has been positive and negotiations with\r\nrespect to specific terms regarding such a study are ongoing. The project will, however, need\r\nadditional funding and applications for study grants are being prepared. \r\n\r\nAppendix 1, Search strategy, study selection and references ‚Äì\r\nQuestion(s) at issue:\r\nDoes mechanical circulatory support with left ventricular assist devices (LVAD) reduce\r\nmorbidity, improve quality of life, and prolong survival in patients with terminal heart failure,\r\nin comparison to optimal medical treatment?\r\nPICO: (P=Patient I=Intervention C=Comparison O=Outcome)\r\nPICO 1\r\nP = Patients with terminal left ventricular heart\r\nfailure despite optimal medical treatment\r\nI = Implantation of a left ventricular assist device\r\nwith pulsatile flow (PF-LVAD)\r\nC = Optimal medical treatment (OMT)\r\nO = Survival, quality of life (QoL), functional\r\ncapacity (NYHA classification, 6 minute walk\r\ntest, exercise test) and biomarkers of heart\r\nfailure. Complications such as infections,\r\nhaemorrhages, thromboembolic events,\r\nneuropsychological functions\r\nPICO 2\r\nP = Patients with terminal left ventricular heart\r\nfailure despite optimal medical treatment\r\nI = Implantation of a left ventricular assist device\r\nwith continous flow (CF-LVAD)\r\nC = Implantation of a left ventricular assist device\r\nwith pulsatile flow (PF-LVAD)\r\nO = Survival, quality of life, functional capacity\r\n (NYHA classification, 6 minute walk test,\r\n exercise test) and biomarkers of heart failure.\r\n Complications such as infections,\r\n haemorrhages, thromboembolic events,\r\n neuropsychological functions\r\nEligibility criteria\r\nStudy design:\r\nRandomized controlled trials\r\nNon-randomized controlled trials\r\nCase series if ‚â• 30 patients\r\nSystematic reviews\r\nLanguage:\r\nEnglish, Swedish, Danish, Norwegian\r\nPublication date:\r\n2000- \r\n\r\nSelection process ‚Äì flow diagram\r\n\r\nRecords identified through database\r\nsearching\r\n(n =1852)\r\nScreening Included Eligibility Identification\r\nAdditional records identified\r\nthrough other sources\r\n(n =76)\r\nRecords after duplicates removed\r\n(n = 1231)\r\nRecords screened by HTAlibrarians\r\n(n = 1231)\r\nRecords excluded by HTA-librarians. Did\r\nnot fulfil PICO or other eligibility criteria\r\n(n = 1095)\r\nFull-text articles assessed for\r\neligibility by HTA-librarians\r\n(n = 136)\r\nFull-text articles excluded by HTAlibrarians,\r\nwith reasons\r\n(n = 81)\r\n52 = wrong intervention\r\n2 = wrong comparison\r\n1 = wrong outcome\r\n23 = wrong study design\r\n3 = wrong focus\r\nFull-text articles assessed for\r\neligibility by project group\r\n(n = 55)\r\nFull-text articles excluded by project\r\ngroup, with reasons\r\n(n = 30)\r\nSee Appendix 2\r\nStudies included in synthesis\r\n(n =26)\r\nIncluding 4 systematic reviews\r\ncommented upon\r\nSee Appendix 1\r\nassist support devices\r\nSearch strategies\r\nDatabase: Medline & Medline in process (OVID)\r\nDate: 2013-02-26\r\nNo of results: 786\r\n# Searches Results\r\n1 exp Heart Failure/ 79663\r\n2 exp Ventricular Dysfunction, Left/ 19737\r\n3 heart failure.ab,kw,ti. 96006\r\n4 (left adj3 ventric$4 adj3 dysfunction$1).ab,kw,ti. 13158\r\n5 1 or 2 or 3 or 4 142421\r\n6 exp Heart-Assist Devices/ 7680\r\n7 heart-assist device$1.ab,kw,ti. 106\r\n8 left ventric$4 assist device$1.ab,kw,ti. 3102\r\n9 left ventric$4 assist system$1.ab,kw,ti. 338\r\n10 ventric$4 assist device$1.ab,kw,ti. 5143\r\n11 (VAD or LVAD or LVAS).ab,kw,ti. 6602\r\n12 6 or 7 or 8 or 9 or 10 or 11 12798\r\n13\r\n((destination adj3 therapy) or permanent or non-transplant$ or nontransplant$ or non transplant$ or\r\nlongterm or long-term or long term).ab,kw,ti. 553532\r\n14 ((ineligible or \"not eligible\" or \"not candidate$1\" or non-candidate$1) adj4 transplant$).ab,kw,ti. 301\r\n15 13 or 14 553741\r\n16 5 and 12 and 15 1035\r\n17 (animals not (animals and humans)).sh. 3673442\r\n18 (comment or editorial or letter).pt. 1217538\r\n19 16 not 17 1003\r\n20 19 not 18 980\r\n21 limit 20 to (yr=\"2000 -Current\" and (danish or english or norwegian or swedish)) 786\r\nDatabase: PubMed\r\nDate: 2013-02-26\r\nNo of results: 81\r\nSearch Query Items\r\nfound\r\n#32 Search #30 AND #31 81\r\n#31 Search (pubmednotmedline[sb] OR in process[sb] OR publisher[sb]) 1900735\r\n#30 Search #28 NOT #29 836\r\n#29 Search ((animals[mh]) NOT (animals[mh] AND humans[mh])) 3757147\r\n#28 Search #26 NOT #27 859\r\n#27 Search (Editorial[ptyp] OR Letter[ptyp] OR Comment[ptyp]) 1219963\r\n#26\r\nSearch #9 AND #18 AND #22 Filters: Publication date from 2000/01/01; Danish; English;\r\nNorwegian; Swedish 882\r\n#23 Search #9 AND #18 AND #22 1111\r\n#22 Search #19 OR #21 562736\r\n#21\r\nSearch (ineligible[tiab] OR \"not eligible\"[tiab] OR \"not candidate*\"[tiab] OR non-candidate*[tiab])\r\nAND transplant*[tiab] 322\r\n\r\n#19\r\nSearch (destination[tiab] AND therapy[tiab]) OR permanent[tiab] OR non-transplant*[tiab] OR\r\nnontransplant*[tiab] OR non transplant*[tiab] OR longterm[tiab] OR long-term[tiab] OR long\r\nterm[tiab] 562481\r\n#18 Search #11 OR #12 OR #13 OR #14 OR #16 OR #17 13338\r\n#17 Search VAD[tiab] OR LVAD[tiab] OR LVAS[tiab] 6877\r\n#16 Search ventricle* assist device*[tiab] OR ventricul* assist device*[tiab] 5736\r\n#14 Search left ventric* assist system*[tiab] 415\r\n#13 Search left ventric* assist device*[tiab] 3769\r\n#12 Search heart-assist device*[tiab] 106\r\n#11 Search \"Heart-Assist Devices\"[Mesh] 7669\r\n#9 Search #2 OR #4 OR #5 OR #8 151926\r\n#8 Search left[tiab] AND ventric*[tiab] AND dysfunction*[tiab] 25459\r\n#5 Search heart failure[tiab] 97970\r\n#4 Search \"Ventricular Dysfunction, Left\"[Mesh] 19681\r\n#2 Search \"Heart Failure\"[Mesh] 79697\r\nDatabase: EMBASE 1974 to 2013 February 25 (OVID SP)\r\nDate: 2013-02-26\r\nNo of results: 860\r\n# Searches Results\r\n1 exp heart failure/ 264726\r\n2 exp heart left ventricle function/ 30457\r\n3 heart failure.ti,ab,kw. 143477\r\n4 (left adj3 ventric$4 adj3 dysfunction$1).ti,ab,kw. 19064\r\n5 1 or 2 or 3 or 4 317750\r\n6 exp heart assist device/ 8672\r\n7 heart-assist device$1.ti,ab,kw. 488\r\n8 left ventric$4 assist device$1.ti,ab,kw. 4638\r\n9 left ventric$4 assist system$1.ti,ab,kw. 418\r\n10 ventric$4 assist device$1.ti,ab,kw. 7786\r\n11 (VAD or LVAD or LVAS).ti,ab,kw. 9971\r\n12 6 or 7 or 8 or 9 or 10 or 11 17588\r\n13\r\n((destination adj3 therapy) or permanent or non-transplant$ or nontransplant$ or non transplant$ or longterm\r\nor long-term or long term).ti,ab,kw. 723616\r\n14 ((ineligible or \"not eligible\" or \"not candidate$1\" or non-candidate$1) adj4 transplant$).ti,ab,kw. 510\r\n15 13 or 14 723984\r\n16 5 and 12 and 15 1805\r\n17 (animal not (animal and human)).sh. 1361790\r\n18 16 not 17 1796\r\n19\r\nlimit 18 to (embase and (danish or english or norwegian or swedish) and yr=\"2000 -Current\"\r\nand (article or conference paper or \"review\")) 860\r\n\r\nDatabase: The Cochrane Library\r\nDate: 2013-02-26\r\nNo of results: 84\r\nCochrane reviews 0\r\nOther reviews 6\r\nTrials 53\r\nTechnology assessments 20\r\nEconomic evaluations 5\r\nID Search Hits\r\n#1 MeSH descriptor: [Heart Failure] explode all trees 4914\r\n#2 MeSH descriptor: [Ventricular Dysfunction, Left] explode all trees 1479\r\n#3 heart next failure:ti,ab,kw (Word variations have been searched) 8961\r\n#4 left near/3 ventric* near/3 dysfunction*:ti,ab,kw (Word variations have been searched) 2043\r\n#5 #1 or #2 or #3 or #4 10047\r\n#6 MeSH descriptor: [Heart-Assist Devices] explode all trees 146\r\n#7 heart-assist next device*:ti,ab,kw (Word variations have been searched) 150\r\n#8 left next ventric* next assist next device*:ti,ab,kw (Word variations have been searched) 61\r\n#9 left next ventric* next assist next system*:ti,ab,kw (Word variations have been searched) 3\r\n#10 ventric* next assist next device*:ti,ab,kw (Word variations have been searched) 84\r\n#11 VAD or LVAD or LVAS:ti,ab,kw (Word variations have been searched) 213\r\n#12 #6 or #7 or #8 or #9 or #10 or #11 344\r\n#13 #5 and #12 84\r\nDatabase: CRD\r\nDate: 2013-02-26\r\nNo of results: 39\r\nLine Search Hits\r\n1 (\"heart failure\") 1239\r\n2 (left ventric* dysfunction*) 89\r\n3 MeSH DESCRIPTOR Heart Failure EXPLODE ALL TREES 511\r\n4 MeSH DESCRIPTOR Ventricular Dysfunction, Left EXPLODE ALL TREES 91\r\n5 #1 OR #2 OR #3 OR #4 1282\r\n6 MeSH DESCRIPTOR Heart-Assist Devices EXPLODE ALL TREES 48\r\n7\r\n(heart-assist device*) OR (left ventric* assist device*) OR (left ventric* assist system*) OR (ventric* assist\r\ndevice*) OR (VAD OR LVAD OR LVAS) 73\r\n8 #6 OR #7 73\r\n9 #5 AND #8 39\r\nThe web-sites of SBU, Kunnskapssenteret and Sundhedsstyrelsen were visited 2013-02-27\r\n2 results\r\nReference lists\r\nA comprehensive review of reference lists brought 76 new records \r\n\r\nReference lists\r\nIncluded studies:\r\nAggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, et al. Incidence and management\r\nof gastrointestinal bleeding with continuous flow assist devices.\r\nAnnals of Thoracic Surgery. 2012;93(5):1534-40.\r\nDaneshmand MA, Rajagopal K, Lima B, Khorram N, Blue LJ, Lodge AJ, et al. Left ventricular assist\r\ndevice destination therapy versus extended criteria cardiac transplant.\r\nAnnals of Thoracic Surgery. 2010;89(4):1205-9; discussion 10.\r\nDembitsky WP, Tector AJ, Park S, Moskowitz AJ, Gelijns AC, Ronan NS, et al. Left ventricular assist\r\ndevice performance with long-term circulatory support: Lessons from the REMATCH trial.\r\nAnnals of Thoracic Surgery. 2004;78(6):2123-30.\r\nDrews T, Stepanenko A, Dandel M, Buz S, Lehmkuhl HB, Hetzer R. Mechanical circulatory support\r\nin patients of advanced age. European Journal of Heart Failure. 2010;12(9):990-4.\r\nGoldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD, et al. Continuousflow\r\nheart transplant\r\nheart transplant \r\ndevices and percutaneous site infections: clinical outcomes.\r\nJ Heart Lung Transplant. 2012;31(11):1151-7.\r\nHolman WL, Park SJ, Long JW, Weinberg A, Gupta L, Tierney AR, et al. Infection in permanent\r\ncirculatory support: heart transplant Experience from the REMATCH trial.\r\nJournal of Heart and Lung Transplantation. 2004;23(12):1359-65.\r\nHutchinson J, Scott DA, Clegg AJ, Loveman E, Royle P, Bryant J, et al. Cost-effectiveness of left\r\nventricular-assist devices in end-stage heart failure.\r\nExpert Review of Cardiovascular Therapy. 2008;6(2):175-85.\r\nKirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS\r\nannual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients.\r\nJournal of Heart and Lung Transplantation. 2013;32(2):141-56.\r\nKirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson L, Miller M, et al. Long-term mechanical\r\ncirculatory support (destination therapy): On track to compete with heart transplantation?\r\nJournal of Thoracic and Cardiovascular Surgery. 2012;144(3):584-603.\r\nLazar RM, Shapiro PA, Jaski BE, Parides MK, Bourge RC, Watson JT, et al. Neurological events\r\nduring long-term mechanical circulatory support for heart failure: the Randomized Evaluation of\r\nMechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) experience.\r\nCirculation. 2004;109(20):2423-7.\r\nLong JW, Kfoury AG, Slaughter MS, Silver M, Milano C, Rogers J, et al. Long-term destination\r\ntherapy with the HeartMate XVE left ventricular assist device: improved outcomes since the\r\nREMATCH study. Congestive Heart Failure. 2005;11(3):133-8.\r\nMorgan JA, Paone G, Nemeh HW, Henry SE, Patel R, Vavra J, et al. Gastrointestinal bleeding with\r\nthe HeartMate II left ventricular assist device. J Heart Lung Transplant. 2012;31(7):715-8.\r\nPark SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, et al. Outcomes in\r\nadvanced heart failure patients with left ventricular assist devices for destination therapy.\r\nCirculation: Heart Failure. 2012;5(2):241-8.\r\nPark SJ, Tector A, Piccioni W, Raines E, Gelijns A, Moskowitz A, et al. Left ventricular assist devices\r\nas destination therapy: a new look at survival.[Erratum appears in J Thorac Cardiovasc Surg. 2005\r\nJun;129(6):1464]. J Thorac Cardiovasc Surg. 2005;129(1):9-17. \r\n\r\nRichenbacher WE, Naka Y, Raines EP, Frazier OH, Couper GS, Pagani FD, et al. Surgical\r\nmanagement of patients in the REMATCH trial.\r\nThe Annals of thoracic surgery. 2003(6 Suppl):S86-92.\r\nRogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of\r\ncontinuous-flow left ventricular assist devices as destination therapy.\r\nCirculation: Heart Failure. 2012;5(1):10-6.\r\nRogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, et al. Chronic Mechanical\r\nCirculatory Support for Inotrope-Dependent Heart Failure Patients Who Are Not Transplant\r\nCandidates. Results of the INTrEPID Trial.\r\nJournal of the American College of Cardiology. 2007;50(8):741-7.\r\nRose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use\r\nof a left ventricular assist device for end-stage heart failure.\r\nNew England Journal of Medicine. 2001;345(20):1435-43.\r\nSharma V, Deo SV, Stulak JM, Durham LA, 3rd, Daly RC, Park SJ, et al. Driveline infections in left\r\nventricular assist devices: implications for destination therapy.\r\nAnnals of Thoracic Surgery. 2012;94(5):1381-6.\r\nSlaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart\r\nfailure treated with continuous-flow left ventricular assist device. New England Journal of Medicine.\r\n2009;361(23):2241-51.\r\nTopilsky Y, Pereira NL, Shah DK, Boilson B, Schirger JA, Kushwaha SS, et al. Left ventricular assist\r\ndevice therapy in patients with restrictive and hypertrophic cardiomyopathy.\r\nCirculation: Heart Failure. 2011b;4(3):266-75.\r\nSystematic reviews and other publications, no appraisal done, only commented on:\r\nAngermayr L, Velasco Garrido M, Busse R. Ventricular assist devices for heart failure.\r\nGMS Health Technol Assess. 2007;3:Doc10.\r\nClegg AJ, Scott DA, Loveman E, Colquitt J, Hutchinson J, Royle P, et al. The clinical and costeffectiveness\r\nof left ventricular assist devices for end-stage heart failure: a systematic review and\r\neconomic evaluation. Health Technol Assess. 2005;9(45):1-132, iii-iv.\r\nRector TS, Taylor BC, Greer N, Rutks I, and Wilt TJ. Use of Left\r\nVentricular Assist Devices as Destination Therapy in End-Stage Congestive Heart Failure: A\r\nSystematic Review. Washington DC2012 May. VA-ESP Project #09-009; 2012.\r\nRogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectivenss analysis of\r\ncontinous-flow left ventricular assist devices as destination therapy. Circ:Heart Fail 2012;5:10-16.\r\nSas G, Boothroyd LJ, Guertin JR, Lambert LJ, Morin JE, Chakor H, et al. Evaluation of the evidence\r\non the HeartMate II and HeartWare ventricular assist devices for the treatment of chronic end-stage\r\nheart failure (Structured abstract). Health Technology Assessment Database. 2012(1).\r\nExcluded studies:\r\nAdamson RM, Dembitsky WP, Baradarian S, Chammas J, May-Newman K, Chillcott S, et al. Aortic\r\nvalve closure associated with HeartMate left ventricular device support: Technical considerations and\r\nlong-term results. Journal of Heart and Lung Transplantation. 2011;30(5):576-82.\r\nAdzic A, Patel SR, Maybaum S. Impact of adverse events on ventricular assist device outcomes.\r\nCurrent Heart Failure Reports. 2013;10(1):89-100. \r\n\r\nAggarwal A, Raghuvir R, Eryazici P, MacAluso G, Sharma P, Blair C, et al. The development of\r\naortic insufficiency in continuous-flow left ventricular assist device-supported patients.\r\nAnnals of Thoracic Surgery. 2013;95(2):493-8.\r\nBackes D, Van den Bergh WM, Van Duijn AL, Lahpor JR, van Dijk D, Slooter AJC. Cerebrovascular\r\ncomplications of left ventricular assist devices.\r\nEuropean Journal of Cardio-Thoracic Surgery. 2012;42(4):612-20.\r\nBarbone A, Pini D, Grossi P, Bandera A, Manasse E, Citterio E, et al. Aspergillus left ventricular\r\nassist device endocarditis. Ital Heart J. 2004;5(11):876-80.\r\nBrush S, Budge D, Alharethi R, McCormick AJ, MacPherson JE, Reid BB, et al. End-of-life decision\r\nmaking and implementation in recipients of a destination left ventricular assist device.\r\nJ Heart Lung Transplant. 2010;29(12):1337-41.\r\nCowger J, Sundareswaran K, Rogers JG, Park SJ, Pagani FD, Bhat G, et al. Predicting Survival in\r\nPatients Receiving Continuous Flow Left Ventricular Assist Devices: The HeartMate II Risk Score.\r\nJournal of the American College of Cardiology. 2013;61(3):313-21. Epub 2012/12/26.\r\nCoyle LA, Ising MS, Gallagher C, Bhat G, Kurien S, Sobieski MA, et al. Destination therapy: oneyear\r\noutcomes in patients with a body mass index greater than 30. Artificial Organs. 2010;34(2):93-7.\r\nDrakos SG, Janicki L, Horne BD, Kfoury AG, Reid BB, Clayson S, et al. Risk Factors Predictive of\r\nRight Ventricular Failure After Left Ventricular Assist Device Implantation.\r\nAmerican Journal of Cardiology. 2010;105(7):1030-5.\r\nDrews T, Dandel M, Krabatsch T, Potapov E, Stepanenko A, Hennig E, et al. Long-term mechanical\r\ncirculatory support in 198 patients: largest single-center experience worldwide.\r\nASAIO Journal. 2011;57(1):9-16.\r\nGirling AJ, Freeman G, Gordon JP, Poole-Wilson P, Scott DA, Lilford RJ. Modeling payback from\r\nresearch into the efficacy of left-ventricular assist devices as destination therapy.\r\nInternational Journal of Technology Assessment in Health Care. 2007;23(2):269-77.\r\nHasin T, Topilsky Y, Schirger JA, Li Z, Zhao Y, Boilson BA, et al. Changes in renal function after\r\nimplantation of continuous-flow left ventricular assist devices.\r\nJ Am Coll Cardiol. 2012;59(1):26-36. Epub 2011/12/24.\r\nHolman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, et al. Predictors of death and\r\ntransplant in patients with a mechanical circulatory support device: a multi-institutional study.\r\nJ Heart Lung Transplant. 2009a;28(1):44-50.\r\nHolman WL, Pae WE, Teutenberg JJ, Acker MA, Naftel DC, Sun BC, et al. INTERMACS: interval\r\nanalysis of registry data.\r\nJournal of the American College of Surgeons. 2009b;208(5):755-61; discussion 61-2.\r\nKushnir VM, Sharma S, Ewald GA, Seccombe J, Novak E, Wang IW, et al. Evaluation of GI bleeding\r\nafter implantation of left ventricular assist device. Gastrointestinal Endoscopy. 2012;75(5):973-9.\r\nLietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Impact of center volume\r\non outcomes of left ventricular assist device implantation as destination therapy: analysis of the\r\nThoratec HeartMate Registry, 1998 to 2005. Circulation: Heart Failure. 2009;2(1):3-10.\r\nLietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left\r\nventricular assist device implantation as destination therapy in the post-REMATCH era: implications\r\nfor patient selection. Circulation. 2007;116(5):497-505. \r\n\r\nLong JW, Healy AH, Rasmusson BY, Cowley CG, Nelson KE, Kfoury AG, et al. Improving outcomes\r\nwith long-term \"destination\" therapy using left ventricular assist devices.\r\nJ Thorac Cardiovasc Surg. 2008;135(6):1353-60; discussion 60-1.\r\nPetrucci RJ, Rogers JG, Blue L, Gallagher C, Russell SD, Dordunoo D, et al. Neurocognitive function\r\nin destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device\r\nsupport.\r\nJ Heart Lung Transplant. 2012;31(1):27-36.\r\nOz MC, Gelijns AC, Miller L, Wang C, Nickens P, Arons R, et al. Left ventricular assist devices as\r\npermanent heart failure therapy: the price of progress.\r\nAnnals of Surgery. 2003;238(4):577-83; discussion 83-5.\r\nRaymond AL, Kfoury AG, Bishop CJ, Davis ES, Goebel KM, Stoker S, et al. Obesity and left\r\nventricular assist device driveline exit site infection. Asaio J. 2010;56(1):57-60. Epub 2010/01/07.\r\nRogers JG, Aaronson KD, Boyle AJ, Russell SD, Milano CA, Pagani FD, et al. Continuous Flow Left\r\nVentricular Assist Device Improves Functional Capacity and Quality of Life of Advanced Heart\r\nFailure Patients. Journal of the American College of Cardiology. 2010;55(17):1826-34.\r\nSlaughter MS, Sobieski MA, 2nd, Graham JD, Pappas PS, Tatooles AJ, Koenig SC. Platelet activation\r\nin heart failure patients supported by the HeartMate II ventricular assist device.\r\nInternational Journal of Artificial Organs. 2011b;34(6):461-8.\r\nSlaughter MS, Bostic R, Tong K, Russo M, Rogers JG. Temporal changes in hospital costs for left\r\nventricular assist device implantation. Journal of Cardiac Surgery. 2011a;26(5):535-41.\r\nStevenson LW, Miller LW, Desvigne-Nickens P, Ascheim DD, Parides MK, Renlund DG, et al. Left\r\nventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset\r\nanalysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of\r\nChronic Heart Failure). Circulation. 2004(8):975-81.\r\nStruber M, Sander K, Lahpor J, Ahn H, Litzler PY, Drakos SG, et al. HeartMate II left ventricular\r\nassist device; early European experience.\r\nEuropean Journal of Cardio-Thoracic Surgery. 2008;34(2):289-94.\r\nTeuteberg JJ, Ewald GA, Adamson RM, Lietz K, Miller LW, Tatooles AJ, et al. Risk assessment for\r\ncontinuous flow left ventricular assist devices: does the destination therapy risk score work? An\r\nanalysis of over 1,000 patients. Journal of the American College of Cardiology. 2012;60(1):44-51.\r\nTopilsky Y, Oh JK, Shah DK, Boilson BA, Schirger JA, Kushwaha SS, et al. Echocardiographic\r\npredictors of adverse outcomes after continuous left ventricular assist device implantation.\r\nJacc: Cardiovascular Imaging. 2011a;4(3):211-22.\r\nVrtovec B, Radovancevic R, Delgado RM, Radovancevic B, Bracey AW, Gregoric ID, et al.\r\nSignificance of anaemia in patients with advanced heart failure receiving long-term mechanical\r\ncirculatory support. European Journal of Heart Failure. 2009;11(10):1000-4.\r\nWestaby S, Siegenthaler M, Beyersdorf F, Massetti M, Pepper J, Khayat A, et al. Destination therapy\r\nwith a rotary blood pump and novel power delivery.\r\nEuropean Journal of Cardio-Thoracic Surgery. 2010;37(2):350-6.\r\nOther references:\r\nBraunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. Fifth. Philadelphia, PA: WB\r\nSaunders Company; 1997. pp. 783‚Äì801.\r\n[Checklist from SBU regarding cohort studies. Version 2010:1]. [Internet]. [cited 2012 Mar 8] \r\n\r\nAvailable from:\r\nhttp://www.sahlgrenska.se/upload/SU/HTAcentrum/Hj\%c3\%a4lpmedel\%20under\%20projektet/B03_Granskningsmall\%20f\%c3\%b6r\%20kohorts\r\ntudier\%20med\%20kontrollgrupper.doc\r\n[Checklists from SBU regarding randomized controlled trials. [Internet]. [cited 2012 Mar 8] Available\r\nfrom:\r\nhttp://www.sahlgrenska.se/upload/SU/HTAcentrum/Hj\%c3\%a4lpmedel\%20under\%20projektet/B02_Granskningsmall\%20f\%c3\%b6r\%20random\r\niserad\%20kontrollerad\%20pr\%c3\%b6vning.doc\r\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task\r\nForce for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European\r\nSociety of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of\r\nthe ESC. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, B√∂hm M, Dickstein K, Falk V,\r\nFilippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, K√∏ber L, Lip GY, Maggioni AP,\r\nParkhomenko A, Pieske BM, Popescu BA, R√∏nnevik PK, Rutten FH, Schwitter J, Seferovic P,\r\nStepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines.\r\nEur Heart J. 2012 Jul;33(14):1787-847.\r\nGRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004\r\nJun 19;328(7454):1490-4.\r\nGRADE Working Group. List of GRADE working group publications and grants [Internet]. [Place\r\nunknown]: GRADE Working Group, c2005-2009 [cited 2012 Mar 8]. Available from:\r\nhttp://www.gradeworkinggroup.org/publications/index.htm\r\nMoher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting\r\nitems for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med.\r\n2009 Jul 21;6(7):e1000097.\r\nPacker M, The neurohormonal hypothesis: a theory to explain the mechanism of disease progression\r\nin heart failure. J Am Coll Cardiol. 1992 Jul;20(1):248-54\r\nSocialstyrelsen (2008). Hj√§rtsvikt. Vetenskapligt underlag f√∂r Nationella riktlinjer f√∂r hj√§rtsjukv√•rd\r\n2008. [Elektronisk]. Stockholm:\r\nSocialstyrelsen. Tillg√§nglig:< http://www.socialstyrelsen.se/nationellariktlinjerforhjartsjukvard/>\r\nZarrinkoub R, Wettermark B, W√§ndell P, Mejhert M, Szulkin R, Ljunggren G, Kahan T. The\r\nepidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail.\r\n2013 Sep;15(9):995-1002.\r\n2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of\r\nCardiology Foundation/American Heart Association Task Force on practice guidelines. Yancy CW,\r\nJessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T,\r\nJanuzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell\r\nJE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College\r\nof Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.\r\nCirculation. 2013 Oct 15;128(16):e240-327.\r\nAppendix 2 ‚Äì Included studies with control groups‚Äì design and patient characteristics.\r\nPF-LVAD = Pulsatile flow left ventricular device, CF-LVAD = Continuous flow left ventricular device, OMT =Optimal medical therapy.\r\n\r\nAuthor,\r\nYear,\r\nCountry\r\nStudy Design Study\r\nDuration\r\n(years)\r\nStudy\r\nGroups;\r\nIntervention\r\nvs control\r\nPatients\r\n(n)\r\nMean Age\r\n(years (sd))\r\nMen (\%) Outcome variables\r\nRose,\r\n2001\r\nUSA\r\nRCT 0 ‚Äì 2.5 PF-LVAD\r\nOMT\r\n68\r\n61\r\n66 (9)\r\n68 (8)\r\n78\r\n82\r\n1) Mortality\r\n2) Functional capacity\r\n3) Quality of life\r\nRogers,\r\n2007\r\nUSA\r\nNon-randomised\r\ncontrolled study\r\n0 ‚Äì 3.5 PF-LVAD\r\nOMT\r\n37\r\n18\r\n60 (11)\r\n58 (10)\r\n92\r\n78\r\n1) Mortality\r\n2) Functional capacity\r\n3) Quality of life\r\nSlaughter,\r\n2010\r\nUSA\r\nRCT 2 PF-LVAD\r\nCF-LVAD\r\n66\r\n134\r\n63 (12)\r\n62 (12)\r\n92\r\n81\r\n1) Mortality\r\n2) Functional capacity\r\n3) Quality of life\r\nDrews,\r\n2010\r\nGermany\r\nNon-randomised\r\ncontrolled study\r\n2 PF-LVAD\r\nCF-LVAD\r\n64\r\n110\r\n64 (3)\r\nrange 60 -73\r\n67 (4)\r\nrange 60 ‚Äì 80\r\n95\r\n89\r\n1) Mortality\r\nKirklin,\r\n2012\r\nUSA\r\nNon-randomised\r\ncontrolled study\r\n0 ‚Äì 5.5 PF-LVAD\r\nCF-LVAD\r\n127\r\n1 160\r\n54.7\r\n63.6\r\nNot\r\nreported\r\n1) Mortality\r\nAppendix 3. Excluded articles - Left venticular assist device as destination therapy\r\nStudy\r\n(author, publication year)\r\nReason for exclusion\r\nAdamson 2011 To few cases\r\nAdzic 2013 No new information\r\nAggarwal 2013 Not included in PICO\r\nBackes 2012 Mixed population\r\nBarbone 2004 To few cases\r\nBrush 2010 Not included in PICO\r\nCowger 2013 Wrong question\r\nCoyle 2010 Not included in PICO, mixed population\r\nDrakos 2010 Mixed population\r\nDrews 2011 Mixed population\r\nGirling 2007 Theoretic model of cost-effectiveness in LVAD patients\r\nHasin 2012 Unclear data\r\nHolman 2009a Not included in PICO, predictors\r\nHolman 2009b Substudy of another study\r\nKushnir 2012 Mixed population\r\nLietz 2009 Not included in PICO, analysis of risk factors\r\nLietz 2007 Not included in PICO, risk score\r\nLong 2008 To few patients\r\nOz 2003\r\nPresentation only of absolute costs of PF-LVADs. No\r\nhealth economy analysis.\r\nPetrucci 2012 Not included in PICO\r\nRaymond 2010 Question not included in PICO\r\nRogers 2010 Not included in PICO\r\nSlaughter 2011a Substudy of Slaughter 2009 (included)\r\nSlaughter 2011b Effect not included in PICO\r\nStevenson 2004 Not included in PICO, risk factor analysis\r\nStruber 2008 Mixed population\r\nTeuteberg 2012 Not included in PICO, risk score analysis\r\nTopilsky 2011b Not included in PICO, echocardiographic predictors\r\nWestaby 2010 Unclear data\r\nVrotec 2009 Mixed population\r\nAppendix 4. LVAD pulsative flow in comparison with optimal medical management\r\nOutcome variables: a) Mortality b) Functional capacity c) Quality of life\r\nAuthor, year Country Study\r\ndesign\r\nNumber\r\nof\r\npatients\r\nn=\r\nFollowup\r\nWith\r\ndrawals\r\n-\r\ndropouts\r\nResult Comments\r\nDirectness*\r\nStudy limitations\r\n*\r\nPrecision *\r\nIntervention Control\r\n* + No problem\r\n ? Some problems\r\n - Major problems\r\na) Mortality\r\nRose, 2001 USA RCT I: 68\r\nC: 61\r\nFU: Not\r\nreported\r\nI: 0\r\nC: 2\r\n1-year survival\r\n52\%\r\np=0.002\r\n2-year survival\r\n23\%\r\nNS\r\n1-year survival\r\n25\%\r\n2-year survival\r\n8\%\r\n? + +\r\nRogers, 2007 USA Nonrandomised\r\ncontrolled\r\nstudy\r\nI: 37\r\nC: 18\r\nFU: 12\r\nmonths\r\nNot\r\nreported\r\n1-year survival\r\n27\%\r\np=0.02\r\n1-year survival\r\n11\%\r\nPatients in the control group\r\nchose not to undergo LVAD\r\nimplantation, which resulted in\r\nsocio-economical imbalance.\r\n- - -\r\nAppendix 4. LVAD pulsative flow in comparison with optimal medical management\r\nOutcome variables: a) Mortality b) Functional capacity c) Quality of life\r\nAuthor, year Country Study\r\ndesign\r\nNumber\r\nof\r\npatients\r\nn=\r\nFollowup\r\nWith\r\ndrawals\r\n-\r\ndropouts\r\nResult Comments\r\nDirectness*\r\nStudy limitations\r\n*\r\nPrecision *\r\nIntervention Control\r\n* + No problem\r\n ? Some problems\r\n - Major problems\r\nb) Functional\r\ncapacity\r\nRose, 2001 USA RCT I: 68\r\nC: 61\r\nI: 0\r\nC: 2\r\nWalking one block\r\n(not limited at all)\r\n16/23\r\np=0.04\r\nSF-36 (physical)\r\n46 (sd 19)\r\np=0.01\r\nWalking one block\r\n(not limited at all)\r\n1/11\r\nSF-36 (physical)\r\n21 (sd 21)\r\n? + +\r\nRogers, 2007 USA Nonrandomised\r\ncontrolled\r\nstudy\r\nI: 37\r\nC: 18\r\nNot\r\nreported\r\nNYHA\r\n85\% Class I-II\r\nNYHA\r\n0\% Class I-II\r\nNo statistical inference test - - -\r\nc) Quality of life\r\nRose, 2001 USA RCT I: 68\r\nC: 61\r\nI: 0\r\nC: 2\r\nMLHF-score\r\n41 (sd 22)\r\np=0.11\r\nMLHF-score\r\n58 (sd 21)\r\nMLHF=Minnesota Living with\r\nHeart Failure questionnaire\r\n? + +\r\nRogers, 2007 USA Nonrandomised\r\ncontrolled\r\nstudy\r\nI: 37\r\nC:18\r\nNot\r\nreported\r\nMLHF-score and\r\nSF-36 ‚Äúimproved‚Ä?\r\nToo few OMT patients for\r\nmeaningful comparison.\r\n- - -\r\nAppendix 5. LVAD continuous flow in comparison with pulsatile flow LVAD\r\nOutcome variables: a) Mortality b) Functional capacity c) Quality of life\r\nAuthor, year Country Study\r\ndesign\r\nNumber\r\nof\r\npatients\r\nn=\r\nFollowup\r\nWith\r\ndrawals\r\n-\r\ndropouts\r\nResult Comments\r\nDirectness*\r\nStudy limitations\r\n*\r\nPrecision *\r\nIntervention Control\r\n\r\n* + No problem\r\n ? Some problems\r\n - Major problems\r\na) Mortality\r\nSlaughter, 2009 USA RCT I: 134\r\nC: 66\r\nFU:\r\n2 years\r\nI: 19\r\nC: 32\r\n1-year survival\r\n68\%\r\n2-year survival\r\n58\%\r\np=0.008*\r\n1-year survival\r\n55\%\r\n2-year survival\r\n24\%\r\n? +\r\n(?)\r\n?\r\nDrews, 2010 Germany Nonrandomised\r\n\r\ncontrolled\r\nstudy\r\nI: 110\r\nC: 64\r\nFU:\r\n2 years\r\nNot\r\nreported\r\n1-year survival:\r\n36\%\r\n2-year survival:\r\n26\%\r\np=0.0017*\r\n1-year survival:\r\n15\%\r\n2-year survival:\r\n12\%\r\n- - ?\r\nKirklin, 2012 USA Nonrandomised\r\n\r\ncontrolled\r\nstudy\r\nI: 1,160\r\nC: 127\r\nNot\r\nreported\r\n:\r\n1-year survival\r\n76\%\r\n2-year survival\r\n67\%\r\np<0.0001*\r\n1-year survival\r\n68\%\r\n2-year survival\r\n45\%\r\nHistorical controls - ? +\r\nAppendix 5. LVAD continuous flow in comparison with pulsatile flow LVAD\r\nOutcome variables: a) Mortality b) Functional capacity c) Quality of life\r\nAuthor, year Country Study\r\ndesign\r\nNumber\r\nof\r\npatients\r\nn=\r\nFollowup\r\nWith\r\ndrawals\r\n-\r\ndropouts\r\nResult Comments\r\nDirectness*\r\nStudy limitations\r\n*\r\nPrecision *\r\nIntervention Control\r\n* + No problem\r\n ? Some problems\r\n - Major problems\r\nc) Functional\r\n capacity\r\nSlaughter, 2009 USA RCT I: 134\r\nC: 66\r\nFU:\r\n1 year\r\nI: 19\r\nC: 32\r\n6 minutes walk test\r\nn=61\r\n318 meters (sd 164),\r\nNS\r\nNYHA\r\n76\% Class I-II\r\nNS\r\n6 minutes walk test\r\nn=12\r\n306 meters (sd 145)\r\nNYHA\r\n:61\% Class I-II\r\n ? +\r\n(?)\r\n?\r\nd) Quality of life\r\nSlaughter, 2009 USA RCT I: 134\r\nC: 66\r\nFU:\r\n1 year\r\nI: 19\r\nC: 32\r\nMLHF-score\r\n34(sd 22)\r\np=0.03\r\nMLHF-score\r\n44 (sd 23)\r\nMLHF=Minnesota Living with\r\nHeart Failure questionnaire\r\n? +\r\n?)\r\n?\r\nAppendix 6 Complications\r\nAuthor. year Country Number\r\nof patients\r\nn=\r\nLength of\r\nfollow-up\r\nType of\r\ndevice\r\nInfections Bleeding Neurological\r\ncomplications\r\nComments\r\n\r\nDembitsky. 2004 USA n=68\r\nunclear\r\nPF-LVAD Sepsis 0.51\r\nLocal 0.35\r\n0.6 0.44 Events/patient/Year\r\nData from REMATCH\r\nDrews. 2010 Germany\r\nn=64\r\nmean 157\r\ndays\r\nPF-VAD 27 \% 3 \% Stroke: 20\% Cause of mortality\r\nHolman. 2004 USA n=68\r\nmedian\r\n408 days\r\nPF-LVAD 42 \% Sepsis\r\nData from REMATCH\r\nLazar. 2004 USA n=68\r\nunclear\r\nPF-LVAD Neurological event: 44\r\n\%\r\nStroke: 16 \%\r\nData from REMATCH\r\nLong. 2005 USA n=42\r\nmean 232\r\ndays\r\nPF-LVAD Sepsis: 0.19\r\nLocal: 0.45\r\nPercutaneous: 0.04\r\nPerioperative: 0.15\r\nLater: 0.38\r\n0.15 Events/Patient/Year\r\nPark. 2005 USA n=68\r\n3 year\r\nPF-LVAD Sepsis: 30 \% Perioperative\r\nbleeding: 1.5 \%\r\n10 \% REMATCH 3-year data\r\nCause of mortality\r\nRichenbacher. 2003 USA n=68\r\nunclear\r\nPF-LVAD Sepsis 0.53\r\nLocal: 0.33\r\nPercutaneous or pocket\r\nsite: 0.36\r\nLate bleeding: 0.53 Data from REMATCH\r\nEvents/Patient/Year\r\nRogers. 2007 USA n=37\r\n6 months\r\nPF-LVAD 0.25 Cerebrovascular\r\ndysfunction: 0.11\r\nStroke: 0.08\r\nEvents/patient-month\r\nRose. 2001 USA n=68\r\nmedian\r\n408 days\r\nPF-LVAD Sepsis: 0.6\r\nLocal: 0.39\r\nDriveline: 0.41\r\n0.56 0.39 The REMATCH trial\r\nEvents/patient/Year \r\nAppendix 6 Complications\r\nAuthor. year Country Number\r\nof patients\r\nn=\r\nLength of\r\nfollow-up\r\nType of\r\ndevice\r\nInfections Bleeding Neurological\r\ncomplications\r\nComments\r\n\r\nAggarwal. 2012 USA n=101\r\nunclear\r\nCF-LVAD 23\% Gastrointestinal bleeding\r\nDrews. 2010 Germany\r\nn=110\r\nmean 281\r\ndays\r\nCF-LVAD 22 \% 6 \% Stroke: 25\% Cause of mortality\r\nGoldstein. 2012 USA n=2006\r\n8 months\r\nCF-LVAD 9.8 \% Driveline infections. Data from\r\nINTERMACS\r\nKirklin. 2012 USA n=1160\r\n1 year\r\nCF-LVAD 8.1 11.9 1.86 Events/100 patient-months\r\nKirklin. 2013 USA n=6561 Mostly\r\nCF-LVAD\r\nDevice related\r\ninfections\r\n15 \%. 1 year\r\n30 \% 2 years\r\n11 \%. 1 year\r\n17 \%. 2 years\r\nData from INTERMACS\r\nDaneshmand. 2010 USA 60\r\nunclear\r\nCF-LVAD 35 \% Driveline infection\r\nMorgan. 2012 USA n=86\r\nmedian\r\n176 days\r\nCF-LVAD 22 \% Gastrointestinal bleeding\r\nPark. 2012 USA n=281\r\nmedian 1.7\r\nyears\r\nCF-LVAD Sepsis: 0.27\r\nLocal: 0.49\r\nDevice related: 0.27\r\nRequiring surgery:\r\n0.14\r\nNeurological event:\r\n0.2\r\nStroke 0.08\r\nEvents/Patient/Year\r\nSharma. 2012 USA n=143\r\nunclear\r\nCF-LVAD Driveline: 12 \% Events/Patient/Year\r\nSlaughter. 2009 USA n=134 CF-LVAD Sepsis: 0.39\r\nDevice related: 0.48\r\nRequiring surgery:\r\n0.23\r\nStroke: 0.13\r\nOther neurological\r\nevent: 0.17\r\nRCT\r\nEvents/Patient/Year\r\nTotal 211 patient-years\r\nTopilsky 2011a USA n=83\r\n30 days\r\nCF-LVAD 59 \% 82\% 14 \%\r\nAppendix 7 - Summary of Findings.\r\nRRR = Relative Risk Reduction; ARR = Absolute Risk Reduction. MLHF=Minnesota Living with Heart Failure. 6MWT=6-minute walk test.\r\nOutcome\r\nvariable\r\nNumber of\r\nstudies\r\nDesign Study\r\nlimitations\r\nConsistency Directness Precision Publication\r\nbias\r\nMagnitude\r\nof\r\neffect\r\nRelative\r\neffect\r\n(95\%CI)\r\nAbsolute\r\neffect\r\n(95\%CI)\r\nQuality of\r\nevidence\r\nGRADE\r\nPF-LVAD versus optimal medical therapy\r\nMortality\r\n2\r\n1 RCT\r\n1 nonrandomised\r\n\r\nstudy\r\nNo serious\r\nlimitations\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)1\r\nUncertain\r\nprecision\r\n(?)2\r\nUnlikely Not\r\nrelevant\r\n1-year:\r\nRRR:\r\n33 \%\r\n18\%\r\n1-year:\r\nARR:\r\n27\%\r\n16 \%\r\nÔÉÖÔÉÖÔÉÖÔÇ?\r\nQuality of life\r\n2\r\n1 RCT\r\n1 nonrandomised\r\n\r\nstudy\r\nVery serious\r\nlimitations\r\n(-2)3\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)\r\nSerious\r\nimprecision\r\n(-1)4\r\nUnlikely Not\r\nrelevant\r\nMLHF\r\nscore\r\n(0-105):\r\n- 29 \%\r\nMLHF\r\nscore\r\n(0-105):\r\n-17 points\r\nÔÉÖÔÇ?ÔÇ? ÔÇ?\r\nFunctional\r\ncapacity\r\n2\r\n1 RCT\r\n1 nonrandomised\r\n\r\nstudy\r\nVery serious\r\nlimitations\r\n(-2)3\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)\r\nSerious\r\nimprecision\r\n(-1)4\r\nUnlikely Very large SF-36\r\nphysical\r\nscore\r\n(0-100):\r\n+ 52 \%\r\nSF-36\r\nphysical\r\nscore\r\n(0-100):\r\n+ 24\r\nÔÉÖÔÉÖÔÇ? ÔÇ?\r\nAppendix 7 - Summary of Findings.\r\nRRR = Relative Risk Reduction; ARR = Absolute Risk Reduction. MLHF=Minnesota Living with Heart Failure. 6MWT=6-minute walk test.\r\nOutcome\r\nvariable\r\nNumber of\r\nstudies\r\nDesign Study\r\nlimitations\r\nConsistency Directness Precision Publication\r\nbias\r\nMagnitude\r\nof\r\neffect\r\nRelative\r\neffect\r\n(95\%CI)\r\nAbsolute\r\neffect\r\n(95\%CI)\r\nQuality of\r\nevidence\r\nGRADE\r\nCF-LVAD versus PF-LVAD\r\nMortality 1 RCT\r\n2 nonrandomised\r\n\r\nstudies\r\nSome\r\nlimitations\r\n(?)5\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)\r\nUncertain\r\nprecision\r\n(?)2\r\nUnlikely Not\r\nrelevant\r\n1-year:\r\nRRR:\r\n27\%\r\n24 \% - 52\%\r\n1-year:\r\nARR:\r\n13\%\r\n20\% - 31 \%\r\nÔÉÖÔÉÖÔÉÖÔÇ?\r\nQuality of life 1 RCT Some\r\nlimitations\r\n(?)5\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)\r\nSerious\r\nimprecision\r\n(-1)4\r\nUnlikely Not\r\nrelevant\r\nMLHF\r\nscore\r\n(0-105):\r\n- 23 \%\r\nMLHF\r\nscore\r\n(0-105):\r\n-10 points\r\nÔÉÖÔÉÖÔÇ? ÔÇ?\r\nFunctional\r\ncapacity\r\n1 RCT Some\r\nlimitations\r\n(-2)5\r\nNo\r\ninconsistency\r\nSome\r\nuncertainty\r\n(?)\r\nVery serious\r\nimprecision\r\n(-1)4,6\r\nUnlikely Not\r\nrelevant\r\n6MWT:\r\n+12\r\nmeters\r\nÔÉÖÔÇ? ÔÇ?ÔÇ?\r\nHigh quality of evidence = ÔÉÖÔÉÖÔÉÖÔÉÖ Low quality of evidence = ÔÉÖÔÉÖÔÇ?ÔÇ?\r\nModerate quality of evidence = ÔÉÖÔÉÖÔÉÖÔÇ? Very low quality of evidence = ÔÉÖÔÇ?ÔÇ?ÔÇ?\r\nFootnotes:\r\n1. Unclear recruitment and randomization of eligible individuals\r\n2. Wide 95 \% confidence interval\r\n3. Selected group of survivors analysed.\r\n4. Few patients\r\n5. Per protocol analysis\r\n6. 95 \% confidence interval not stated \r\nAppendix 8 Ethical analysis\r\n1. From the patient\s perspective, how does destination therapy (DT) affect the patient\s\r\nquality of life and life expectancy?\r\nThe patient will have a longer life expectancy, probably with better quality of life and\r\nfunctional capacity. In addition, DT may resolve the contraindication to heart transplantation\r\nand thereby restore transplant eligibility, with further expected improvement in quality of life\r\nand life expectancy.\r\n2. How severe is the patient\s need that the DT must meet?\r\nThe mortality of end stage heart failure is very high, and it is associated with severely reduced\r\nfunctional capacity, poor quality of life and frequent hospitalisations. The 1-year survival for\r\npatients diagnosed with severe heart failure (NYHA IV) on optimal medical treatment is\r\nbelow 50 \%.\r\n3. Does DT influence the view on humanity or human dignity?\r\nNo, probably not from the view of other individuals. However, to have a mechanical device\r\nimplanted in your own body may affect the subject‚Äôs self-esteem and self-image.\r\n4. Can DT affect the patient‚Äôs ability and possibility to be independent?\r\nDT is likely to improve the functional capacity and, thereby, the independency of the patient.\r\nHowever, continuous need for electric power either from a power base unit or from batteries\r\nmay in other ways limit independency. The patient will also need assistance to change the\r\nbandages around the driveline. Thus, total independence will not be achieved.\r\n5. If implemented, does DT require any special steps to not compromise the patient\s\r\nautonomy?\r\nDT is likely to introduce a specific challenge to the patient with respect to autonomy. In this\r\nrespect it is important to inform the patient extensively about the treatment, including\r\npotential benefits and risks. Also, of importance for the patient‚Äôs autonomy is that the DT\r\nprogram should include the following:\r\n1. Participation of a multidisciplinary care team, including palliative care specialists\r\n2. Adopting a concise plan of care for anticipated device-related complications\r\n3. Planning for anticipated end-of-life care and timing of device deactivation\r\n6. How does DT affect the patient‚Äôs physical, moral and personal integrity?\r\nThe moral and personal integrity will most probably not be negatively affected by DT.\r\nHowever the physical integrity is interrupted by the highly invasive nature of the implantation\r\nprocedure.\r\n7. Is DT cost-effective?\r\nAttempts to estimate the cost-effectiveness of DT have reported that incremental costs per\r\nquality-adjusted life years (QALYs) are very high. Thus, the cost-effectiveness of DT is\r\nquestionable.\r\n8. How does DT affect resources?\r\nDT is a costly treatment. Except for the costs of the device and accessories, DT requires the\r\nuse of operation rooms, beds in the intensive care units (sometimes for long periods of time),\r\nmany days in the hospital wards, and frequent outpatient follow-up visits. DT complications\r\nwill also use resources for clinical work-up and treatment. All of this will compete with the\r\nneeds of other patient categories. Thus, unless additional resources can be provided there is a\r\nsubstantial risk that DT will reallocate current resources from other medical needs. \r\nAppendix 8 Ethical analysis\r\n9. Is DT in conflict with professional values?\r\nIn our opinion, the benefits of DT in highly selected patients will outweigh its risks and,\r\ntherefore, are not in conflict with professional values.\r\n10. Does DT change the role of the professional in relation to the patient?\r\nDT is demanding for patients and their families. The patient must be able to comply with the\r\nsystem, e.g. exchange batteries, and interpret and react to signals from the system monitor.\r\nThe bandages around the driveline exit site must be changed regularly with an aseptic\r\ntechnique.\r\n11. Does DT affect, or does it put any new demands on, a third party?\r\nDT is likely to be challenging for the patient‚Äôs family, already from the postoperative phase\r\nand during rehabilitation when the patient is getting accustomed to a new life situation. The\r\ntreatment also demands frequent follow-up visits. Bandage exchanges around the driveline\r\nexit site requires assistance. This is often performed by family members or by professional\r\nhealth care providers.\r\n12. Is there any legislation of relevance with regard to DT?\r\nNo.\r\n13. Is there any risk of conflict between DT and values of the society, or values of\r\ndifferent groups?\r\nTo prolong life with a mechanical device may be in conflict with the beliefs and norms of\r\nsome groups in our society.\r\n14. Is there a risk that an introduction of DT will cause a conflict with particular\r\ninterests?\r\nNo, probably not.\r\n15. Can an introduction of DT influence the trust of the health care system?\r\nDT is a high-risk treatment for severely debilitated patients and may generate several\r\ncomplications. Thus, in order to maintain the credibility of the health care system it is of\r\nutmost importance to inform patients and their families about both the benefits and the risks\r\nof the treatment. Also, prerequisite algorithms for clinical work-up, treatment of possible\r\ncomplications, and other difficult situations that may arise should be established before a DT\r\nprogram is adopted.\r\nCONCLUSIONS\r\nIntroduction of a DT program raises several ethical issues. The self-esteem and self-image of\r\nthe individual patient probably varies between subjects, but may be affected in both positive\r\nand negative ways. The patient will still be dependent on assistance from family members\r\nand/or health care providers, and the physical integrity is affected. Without additional\r\neconomic resources there is a substantial risk that DT will reallocate current resources from\r\nthe needs of other patient categories. \r\nHTA-centrum\r\nSahlgrenska Universitetssjukhuset\r\nHTA\r\nHealth technology assessment (HTA) is the systematic\r\nevaluation of properties, effects, and/or impacts of health\r\ncare technologies, i.e. interventions that may be used to\r\npromote health, to prevent, diagnose or treat disease or for\r\nrehabilitation or long-term care. It may address the direct,\r\nintended consequences of technologies as well as their\r\nindirect, unintended consequences. Its main purpose is to\r\ninform technology-related policymaking in health care.\r\nTo evaluate the quality of evidence the Centre of Health Technology Assessment in Region V√§stra G√∂taland is\r\ncurrently using the GRADE system, which has been developed by a widely representative group of international\r\nguideline developers. According to GRADE the level of evidence is graded in four categories:\r\nHigh quality of evidence = (GRADEÔÉÖÔÉÖÔÉÖÔÉÖ )\r\nModerate quality of evidence = (GRADE ÔÉÖÔÉÖÔÉÖO)\r\nLow quality of evidence = (GRADE ÔÉÖÔÉÖOO)\r\nVery low quality of evidence = (GRADE ÔÉÖOOO)\r\nIn GRADE there is also a system to rate the strength of recommendation of a technology as either ‚Äústrong‚Ä? or\r\n‚Äúweak‚Ä?. This is presently not used by the Centre of Health Technology Assessment in Region V√§stra G√∂taland.\r\nHowever, the assessments still offer some guidance to decision makers in the health care system. If the level of\r\nevidence of a positive effect of a technology is of high or moderate quality it most probably qualifies to be used in\r\nroutine medical care. If the level of evidence is of low quality the use of the technology may be motivated\r\nprovided there is an acceptable balance between benefits and risks, cost-effectiveness and ethical considerations.\r\nPromising technologies, but a very low quality of evidence, motivate further research but should not be used in\r\neveryday routine clinical work.\r\nChristina Bergh, Professor, MD.\r\nHead of HTA-centrum\r\nRegion V√§stra G√∂taland, HTA-centrum\r\nHealth Technology Assessment\r\nRegional activity-based HTA\r\n\r\nFrom operations or activity/management:\r\nQuestion\r\nClinic-based\r\nHTA\r\n‚Ä¢ Training\r\n‚Ä¢ Search, sort, and\r\nselect process\r\n‚Ä¢ Advice, help,\r\nassistance\r\n‚Ä¢ Feedback\r\nQuality assurance Support process\r\nprocess\r\nMain process\r\nExternal\r\nreview\r\nSummarized\r\nassessment\r\nQuality assured decision rationale\r\nFormally\r\ndesignated\r\ngroup for\r\nquality assurance\r\nSahlgrenska Universitetssjukhuset, HTA-centrum\r\nR√∂da Str√•ket 8, 413 45 G√∂teborg\r\nwww.sahlgrenska.se/hta-centrum